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Chapter 1
Introduction
Biotechnologies came to an era where the amount of information one has access to
allows to think about biological objects as complex systems. In this context, the
phenomena emerging from these systems are tightly linked to their organizational
properties. This raises methodological challenges which are precisely the focus of
study of the machine learning community. This thesis is about applications of machine
learning methods to study biological phenomena from a complex systems viewpoint.
This introduction specifies what is meant by system based and machine learning
approaches. The biological applications treated in this manuscript are presented in a
second phase.
1.1 System theoretic approaches in biology
The general idea that a system being made of different parts is, as a whole, something
different from the sum of its parts dates back to antiquity and is rather well accepted
today, specially in the scientific community. This idea is to be linked with the notion
of scale. At any scale, natural objects are parts of larger systems and are themselves
made of different parts. For example, a population of living organisms gathers differ-
ent individuals which could be pluricellular, each cell consisting of an accumulation
of big molecules themselves made of atoms etc . . . This naturally leads to a hierarchy
of objects, which behaviour is related to the scale at which they are observed.
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The first aspect in the understanding of natural objects at a given scale, is the
characterization of the object of study as an isolated entity. For example, in cell
biology, a living cell is made of different compartments, evolves in time following
cell cycle, and could potentially undergo a division. At a different scale, in molec-
ular biology, a protein is a polymer of amino acids that is characterized by a three
dimensional structure and has a specific function such as catalysis of a reaction (en-
zymes), transcription of DNA, or transportation of smaller molecules. The study of
these individual characteristics at one scale helps understanding behaviours at higher
levels in the hierarchy. In relation with the two previous examples, understanding a
phenomenon occurring at the cell level, such as switching from one cell cycle state to
another, requires to decipher the chemical reactions that underlie this process.
However, cell biology can not be reduced to the application of molecular principles.
The reactions affecting cell cycle do not occur at random but rather in a well organized
manner. Taking this global organization into account is crucial in order to understand
molecular basis of cell cycle. It requires tools and methods that go beyond the field of
molecular biology. More generally, the study of interactions between different levels
in the hierarchy of scales requires to consider organization between scales, how small
entities organize themselves to constitute bigger entities. This is referred to as a
system approach. Observing and explaining several phenomena imposes to consider
a set of entities as a whole complex system with specific organizational properties.
What could be the benefits of such an approach? In some cases, one cannot get
by without these considerations. For example, if one is interested in characterization
of the effect of a given chemical compound at the cell level, it is pointless to draw
conclusions based on a single cell experiment. Different types of cells could eventually
respond in different ways. Additionally, cells of the same type coming from the same
population may exhibit variability in behaviour. The structure of inter cell variability
within this population holds information about the underlying biological process.
For instance, cells might not react in the same way whether they are surrounded by
many other cells or not. Taking into account this variability by considering different
cell types and several populations of each cell type is necessary in order to draw
reproducible conclusions from such experiments. This is illustrated in one chapter of
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this thesis.
In other cases the need to consider a system based approach arises from the highly
non linear behaviours of interactions between parts constituting a bigger entity. Many
observable phenomena are non linear in nature. For instance, mass action law, mod-
elling chemical kinetics, can lead to highly non linear dynamics. Accumulating these
non linearities leads to complex behaviours at the system level which investigation is
impossible without such a system approach. Striking examples of this non linearity
are bistable systems which can rest in either of two distinct states. Such systems are
at the heart of triggering mechanisms that occur at the cellular level, such as cell
division, cell differentiation or apoptosis. Chapter 5 of the thesis is dedicated to the
optimization of experimental design for the characterization of non linear dynamical
system.
System based approaches are not necessary in all circumstances. If not required,
they could, however, be beneficial. For example, studying the spatial conformation
at the site where a ligand binds to a protein does not require to take into account the
whole surrounding molecular environment. However considering this specific interac-
tion occurrence as a member of a set of interactions can shed light on the underlying
molecular recognition mechanisms it involves. While all interactions are different,
there might exist general trends in what characterizes an interaction. A system based
approach can take advantage of this property and use it in a prediction context. These
ideas are illustrated in the context of protein ligand interaction prediction and drug
side effect prediction in chapters 3 and 4.
While considering the structural organization of groups of objects can be essen-
tial or beneficial to comprehend complex systems, it is not possible to apply such
ideas in any context. The two main bottlenecks are knowledge and computational
methods. It is required to grasp the characteristics of individual small entities in
order to understand how they are organized at a larger scale. Advances in biological
knowledge and technological abilities to carry out large scale experiments make it
possible today to apply system based reasoning to the study of molecular, cellular
and macroscopic phenomena. For example, large amount of data is now available
about molecular interactions. Moreover, high throughput technologies, such as next
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generation sequencing or high content screening, have substantially accelerated the
data acquisition process and broadened the spread of experiments that could be car-
ried out in a row. This considerably increases the size and complexity of encountered
statistical and computational problems. The so-called machine learning field is ex-
actly at the interface between these two concepts and provides solutions to tackle
problems one faces in applying complex systems reasoning in a biological context.
1.2 Machine learning
While the field of machine learning is very broad, the problems of interest go from
theoretical and empirical performances to statistical and computational trade off,
this paragraph focuses on the specific aspects needed to introduce the work presented
further in this thesis. Broadly speaking, there exists mainly two different ways of
formulating problems addressed in this manuscript. They are referred to as supervised
and unsupervised problems, as informally described here.
Supervised problems consist in the estimation of a functional relation between
two categories of objects based on noisy observations of this relation. Informally, it is
assumed that there exists spaces X and Y and a function f : X → Y . One has access
to noisy realizations of this functional relationship, meaning that several data points
are available which are assumed to be of the form:
yi = f(xi) + ǫi
where xi is in X , yi is in Y and ǫi is random noise. The quantity of interest is
the function f which is unknown. The objective is to estimate this function or to
accurately reproduce it. Many prediction problems can be formalized this way. The
typical example in biology is the response of a system to an external stimulus. In this
case X is a set of possible stimuli, for example chemical compounds, Y is the set of
possible responses of an organism to these stimuli. The nature of the function f and
of the estimation procedure will depend on the structure of the input space X and
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the structure of the output space Y . Classification methods are dedicated to discrete
and known possible values of Y . For example, in the context of predicting protein
targets for ligands, the input space X is the space of chemical compounds, and the
output space Y reflecting the presence or absence of interaction with a given protein.
Regression methods correspond to continuous real output, predicting affinity of a
given compound for a certain protein would fall into this class. These methods are
used in the context of drug target interaction and side effect prediction in chapters
3 and 4. In chapter 5 we specify the function f as reflecting the dynamics of an
underlying dynamical system which we try to characterize based on observation of
the system under different experimental conditions.
As discussed in the previous paragraph, taking into account hierarchical structures
observed at different scales is potentially beneficial in a biological context. Interest-
ingly, it is possible to relate the structure of the biological problem to the structure
of the input space X and the output space Y in a supervised setting. To be concrete,
define the input space X as the space of chemical compounds and the output space
as a binary digit vectors of size p each entry of the vector reflecting the fact that a
given molecule x binds or not to each protein in a set of p proteins. One possibility to
solve this problem is to build one classifier for each protein in the considered set. It
is also possible to adopt a system approach and share information between different
proteins and adapt to the underlying structure of the set of proteins as illustrated in
chapter 3.
Unsupervised problems consist in searching for hidden structures in a set of
unlabelled data. The experimenter is provided with elements xi taken from an input
space X but no label yi is given. Broadly speaking, the problem consists in finding
meaningful trends that characterize well the typical elements taken from the input
space X . These characteristics can be further taken as input to solve supervised
problems. A wide variety of methods are available to address unsupervised problems,
among which three are informaly presented in this paragraph.
“Principal component-type methods” seek direction of large dispersion in a given
dataset. These directions are those that explain observed variability in this dataset.
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While typical datasets encountered in biology can be of very dimension, it happens
that a few factors can explain most of the variations between data points. This
results in a compact representation of the underlying dataset which can be used for
prediction purpose or to understand typical trends in the data. This is illustrated in
the context of drug target interactions and side effects in chapters 3 and 4.
“Clustering-type” methods seek to partition the input dataset into a few cate-
gories. The objective is to output meaningful clusters, data points from the same
cluster being very similar and data points from different clusters sharing much less
similarity. A specific model based clustering method is presented in the context of
cell population phenotyping in chapter 4.
“Density estimation” is the task of defining to which extent typical data points
look like, and to differentiate them from data points which are far from them. Methods
for solving these problems can be used in the context of outlier detection. In this case
one is interested in finding data points that are different from most of the other points,
without a predefined criterion to describe these differences. In chapter 4, the model
developed for cell population phenotyping is used for such purpose in the context of
the study of cell populations.
By nature, unsupervised methods seek to shed light on underlying structure in a
dataset. Thus, they are well suited to tackle biological problems at complex systems
scale. Furthermore, one can put more emphasis on specific structural assumptions
by choosing one type of methods or by adapting a specific method to the context at
hand, as specific examples shown in this thesis will illustrate.
1.3 Contribution and organization of the thesis
The previous paragraph gave a brief overview of the methods that are used in this
work. Chapter 2 provides more technical details and pointers to the literature re-
lated to the specific methods used in the projects that are presented. The remaining
chapters illustrate these methods on specific biological applications. The biological
problems addressed in these chapters constitute relevant questions in drug design
(chapter 3 and 4), interpretation of high throughput imaging technologies (chapter 4)
1.3. CONTRIBUTION AND ORGANIZATION OF THE THESIS 7
and systems biology (chapter 5). Each chapter introduces the biological questions it
addresses as well as related background. The specific focus of interest is put in context
and the contributions of the presented work are described. Specific methodological
details as well as experimental results are then presented.
Chapter 3 focuses on the molecular scale and more specifically on the study of
protein-ligand interactions. Protein-ligand interactions constitute the key molecular
mechanism that drives most important biological processes such as signal transduction
or catalysis of metabolic reactions. They are also of interest in the context of drug
design, the objective being to disrupt a biological process by modifying the behaviour
of one of a protein related to this process, through a molecular interaction with a
drug ligand. Sparse matrix factorization techniques are applied to reveal associations
between chemical substructures and protein domains underlying these interactions.
Examples show that this method extracts relevant information in this context. This
information is further used in a prediction context and show performances comparable
to state-of-the-art methods. An extension of these ideas using very high dimensional
linear classifiers is briefly mentioned.
Chapter 4 presents results related to phenotyping. In a first part, drug side-
effects are investigated using matrix factorization techniques similar to those used
in chapter 3. Drug-side effects are the result of the interactions of a small drug
molecule with all its potential protein targets. The resulting effect can be viewed as a
phenotype for the considered molecules. This chapter focusses on the relation between
drug chemical structure and its side-effects. Examples of modulation of side-effects
through chemical structure and links with protein interaction profiles are proposed.
Performance of the method in the context of supervised side-effect prediction are
compared to those of state-of-the-art classification methods. An extension of this work
involving the integration of both chemical and protein target interactions information
is qualitatively described.
A second part tackles the question of defining cellular phenotypes at the scale of
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cell populations based on fluorescent images. Single cell phenotyping based on flu-
orescent images is a well understood problem. The question of comparing different
populations of cells with variable cellular characteristics is less understood. A genera-
tive model is proposed to tackle this problem. Numerical experiments are carried out
based on high-content screening data recorded to study the Ewing sarcoma disease.
Properties of the proposed model are illustrated through various examples.
Chapter 5 is dedicated to the presentation of a sequential experimental design tool
for dynamical systems characterization. The related biological scale lies in between
the molecular scale considered in chapter 3 and the phenotypic scale considered in
chapter 4. Common models of molecular interactions in systems biology involve non
linear dynamical systems with unknown parameters. Estimating these parameters
from data is crucial to validate and use these models in practice. The non linearities
and the lack of data available lead to parameter non identifiabilities, many different
combinations of parameters agree with available data. The objective is to propose a
strategy that identifies these non identifiabilities and proposes experiments to miti-
gate them. The need for design strategies based on numerical criteria is motivated.
Bayesian and active learning ideas are used to define such a strategy. Numerical
approximations to implement this strategy are provided and simulation results are
presented. All the results presented in this chapter are based on numerical simulations
of the experimental design process. The motivation and materials for designing and
testing this method were provided in the context of DREAM7 Network Parameter
Inference Challenge.
Chapter 2
Methods
Re´sume´
Ce chapitre pre´sente les de´tails algorithmiques et me´thodologiques lie´s aux travaux
pre´sente´s dans ce manuscrit. Son contenu est disponible dans la litte´rature. Ces
re´sultats sont rappele´s ici pour me´moire et afin de donner des liens vers la litte´rature
correspondante, sans chercher a` eˆtre exhaustifs. La premie`re section est de´die´e a` la
pre´sentation de l’algorithme de factorisation parcimonieuse de matrice pre´sente´ par
[129] et qui est utilise´ dans les chapitres 3 et 4. Nous donnons ensuite un aperc¸u des
me´thodes d’apprentissage supervise´ utilise´es dans les meˆmes chapitres, ainsi que leurs
fondements statistiques. La troisie`me section pre´sente les algorithmes d’infe´rence ap-
proche´e utilise´s dans les chapitres 4 et 5 dans le contexte de la mode´lisation proba-
biliste et de la mode´lisation Baye´sienne. La dernie`re section de´crit la proce´dure de
validation croise´e utilise´e pour l’e´valuation de mode`les dans les chapitres 3 et 4.
Abstract
This chapter gathers methodological and algorithmic details related to the work pre-
sented in this manuscript. All the results presented here are available in the literature.
They are recalled here to give pointers to the related articles. The focus is not on
being technically exhaustive. The first section is dedicated to the presentation of the
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sparse matrix factorization of [129] which is used in chapters 3 et 4. A brief overview
of supervised learning methods used in the same chapters is then given, with a rapid
overview of the statistical foundations of these methods. The third section presents
approximation algorithms used for inference in chapters 4 and 5 in the context of
probabilistic and Bayesian modelling. The last section describes the cross validation
scheme used for model assessment in chapters 3 and 4.
2.1 Sparse matrix factorization
The sparse matrix factorization problem is an area of very intense research. From
an algorithmic point of view, the purpose is to approximate an input matrix by the
product of two sparse factor matrices or to find a low rank approximation of the input
matrix which factors are sparse. From a statistical point of view, this is related to the
sparse PCA problem, which is the unsupervised task of separating signal with sparse
structure from the environment noise. Various algorithms have been proposed to
tackle this problem with different statistical and algorithmic properties. This section
describes the algorithm presented in [129] which has low theoretical guaranties but is
applicable to large scale problems. This algorithmic choice is briefly compared to other
possible choices, and applications in unsupervised data analysis are described. They
correspond to the methods used in further chapters. Finally, a validation procedure
based on reconstruction ability of the unsupervised factorization is described.
2.1.1 Singular value decomposition
The method presented in [129] consists in incorporating sparsity-inducing constraints
in a known algorithmic frameworks to solve regular low rank matrix approximation.
First, the singular value decomposition is briefly described. Let Z ∈ Mn×p(R) be a
real matrix with n rows and p columns of rank K ≤ min(n, p). The singular value
decomposition of Z is the unique triplet of matrix (U,D, V ) satisfying
Z = UDV T , UTU = In, V
TV = Ip, d1 ≥ d2 ≥ . . . ≥ dK > 0
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where U is an unitary matrix of size n × n, V an unitary matrix of size p × p a
rectangular matrix of size n × p which entries are null except for the K diagonal
elements given by d1, d2, . . . , dK . Columns of U are eigenvectors of ZZ
T , columns of
V are eigenvectors of ZTZ. Let uk be the columns of U , vk the columns V and dk
the k-th element of the diagonal of D. It is a well known result [30] that
r∑
k=1
dkukv
T
k = argminẐ∈M(r)||Z − Ẑ||F
where M(r) is the set of matrices of dimension n × p with rank r and || · ||F is the
Froebenius norm. The singular value decomposition allows to find the matrix of
rank r which is the best approximation to Z in the sense of the Froebenius norm.
Interestingly, this is a non convex problem which solution is analytically expressible
as an eigenvalue problem. Moreover, it is easy to see that:
(u1, v1) = argmaxu,vu
TZv ||u||2 = ||v||2 = 1. (2.1)
A widely used iterative scheme to compute solutions of the previous problem is to
initialize v(0), such that ||v(0)||2 = 1 and to repeat until convergence :
• u← argmaxu uTZv ||u||2 ≤ 1
• v ← argmaxv uTZv ||v||2 ≤ 1
which reduces to the well known power method,
• v(i+1) = (ZTZ)v(i)
||(ZTZ)v(i)||2
• u(i+1) = (ZZT )v(i)
||(ZZT )u(i)||2
which converges to the largest singular value of Z under the condition that it is higher
than all the others and that v(0) is not orthogonal to the singular vector associated
to this singular value. This scheme allows to compute the leading singular vector,
which, together with a deflation procedure, allows to compute the full decomposition.
1. Z(1) ← Z .
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2. for k ∈ {1, . . . , K}
• find uk, vk et dk using the power method with Z(k)
• Z(k+1) ← Z(k) − dkukvTk
2.1.2 Sparse matrix decomposition
The penalized matrix decomposition algorithm of [129] consists in adding a sparsity
constraint to problem (2.1) and uses the same alternate minimization scheme to solve
the problem. The formulation is as follows:
(u1, v1) = argmaxu,vu
TZv ||u||2 = ||v||2 = 1, ||u||1 ≤ c1, ||v||2 ≤ c2 (2.2)
where c1 and c2 are tuning parameters. The iterative scheme becomes:
• u← argmaxu uTZv ||u||2 ≤ 1, ||u||1 ≤ c1
• v ← argmaxv uTZv ||v||2 ≤ 1, ||v||1 ≤ c2.
The minimization steps in the sub problems is easily solvable. For example, it can be
shown that the first step has a solution of the form:
u← S(Zv, δ1)||S(Zv, δ1)||2 (2.3)
where S is the soft thresholding operator applied to each entry of the vector. It
has the form S : (x, δ) → sign(x)(|x| − δ)+, where (.)+ denotes the positive part.
However, the amount of thresholding δ is unknown. In 2.3, it should be chosen to be
null, δ1 = 0, if the application of 2.3 results in ||u||1 ≤ c1, otherwise, δ1 is a positive
constant such that ||u||1 = c1, where the precise value of the constant is found using
line search.
As described in [129], the method does not come with any algorithmic or statistical
property. It was recently shown in [83] that the proposed alternate minimization
scheme converges to a critical point of problem (2.2). Broadly speaking, methods
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proposed to solve the sparse matrix factorization problem can be divided into two
classes.
1. Convex relaxation methods leading to a semi-definite programming formulation
of the problem, whose global minimizer can be computed, for example [26].
State-of-the-art semi-definite programming algorithms are still computationally
expensive which limit their application on large datasets.
2. On the other hand, local search iterative methods can only produce local optima
for some non convex objective. They are however much less expensive than
convex relaxation methods. They can be applied to larger datasets but cannot
guaranty that the best solution is found due to multiple critical points.
The algorithm presented here is one of the second kind. It does not guaranty global
optimality, but it is much cheaper in term of computation. The algorithm described
in [129] was empirically shown to perform well on high dimensional biological ap-
plications. This algorithmic choice allowed to perform extensive experiments and
parameter tuning on the datasets considered in chapters 3 and 4.
2.1.3 Application in data analysis
Many unsupervised data analysis methods amount to solve problem (2.1) for a given
input matrix. Canonical correlation analysis [55] and canonical correspondence analy-
sis [45] are described in this paragraph. Sparse version of these methods involving the
algorithmic scheme described in the previous paragraph are evaluated on biological
examples in chapters 3 and 4.
Canonical correlation anaylsis. This method allows to study links between two
different representations of the same objects. Let X ∈ Mn×p(R) and Y ∈ Mn×q(R)
be two representations of a set of n objects according to two vector variables of
dimension p and q respectively. Columns of X and Y are centered and scaled. The
matrix XTY is an empirical estimate of the correlation structure based on these n
individuals. The goal is to study underlying correlations between these two variables.
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To do so, we look for linear combinations of variables that are strongly correlated.
This amounts to solve
max
u,v
cor(u, v) =
uTXTY v√
uTXTXu
√
vTY TY v
which is equivalent to
max
u,v
uTXTY v uTXTXu = 1 vTY TY v = 1.
Canonical correspondence analysis. This method allows to study links between
two different sets of objects represented by different variables based on a contingency
table representing co-occurrences of the considered objects. Let X ∈ Mn×p(R) and
Y ∈ Mm×q(R) represent a first set of n objects in dimension p and a second set of
m objects in dimension q. A contingency table A ∈ Mn×m(R) represents the co-
occurrences of the two sets of objects. As for canonical correlation analysis, the goal
is to find linear combinations of variables which are strongly correlated by solving
max
u,v
cor(u, v) =
uTXTAY v√
uTXTDXXu
√
vTY TDY Y v
where DX (resp DY ) is a diagonal matrix which entries are the degree of the categor-
ical variables X (resp Y ). This is equivalent to
max
u,v
uTXTY v uTXTDXXu = 1 v
TY TDY Y v = 1.
Simplification and addition of sparsity-inducing constraints. The methods
described in this paragraph amount to solve numerical problems which structures
are similar to that of (2.1). Empirical evidences suggest that in a high dimensional
context, covariance matrices can be approximated by diagonal matrices [120, 29]. This
simplification leads to the replacement of constraints of the form uTXTXu = 1 by
a simpler constraint ||u||2 = 1. Adding sparsity-inducing constraints leads to sparse
variants of canonical correlation analysis and canonical correspondence analysis which
have the exact same form as that of (2.2) and can be solved using the numerical scheme
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of [129].
The motivation behind the use of sparsity is twofold. Depending on the problem
at hand, it could be expected that principal factors should be sparse. For example, in
the case of protein ligand interactions, as illustrated in chapter 3, physics underlying
the molecular recognition mechanisms suggests that the presence or absence of a
limited number of chemical substructures is a key to explain why a given molecule
binds to a given protein. One can expect gains in performance by accounting for this
hypothesis. Moreover, the factor extracted by the penalised decomposition procedure
should be interpretable for practitioners. In high dimensional settings, this analysis
is much more challenging when the factors are dense, i.e. when they contain many
non zero elements. Enforcing sparsity allows eases the interpretation of the extracted
factors.
2.1.4 Validation in the context of supervised prediction con-
text
Both methods lead to the penalised decomposition of a matrix Z ∈ Mp×q(R) of
the form Z ≃ ∑Ki=1 ρiuivTi for a given number of extracted factors K. Each factor
represents directions of strong correlation in the dataset. Suppose that one is given
two new objects x ∈ Rp and y ∈ Rq. Projecting these objects on the subspace spanned
by the principal factors leads to the following score
s(x, y) =
K∑
i=1
ρix
Tuiv
T
i y
which represents the strength of the association between these new objects based on
the extracted principal factors. This score can be used to make predictions. For
example if x represents an unseen molecule and y represents a known protein, the
score s can be used as a confidence level for the association between x and y. It is
natural to validate unsupervised methods on supervised reconstruction tasks. This
point is illustrated in chapters 3 and 4.
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2.2 Supervised learning
Many state-of-the-art methods for supervised problems are related to the statistical
learning theory. This section proposes an overview of the learning methods used in
this manuscript as baselines to evaluate the performance of the methods proposed
in this thesis. The principle of empirical risk minimization is described first. Kernel
function classes are then briefly described, as well as nearest neighbour methods that
are used for comparison purposed in chapters 3 and 4. The purpose is to motivate
the choice of these methods as comparison points, and to give a very fast overview of
the underlying theory. The book [51] provides detailed materials as well as pointers
to the bibliography.
2.2.1 Empirical risk minimization
Inductive supervised learning is the task of learning a functional relationship based
on examples. Informally, we suppose that there exists an input space X and an
output space Y (usually R for regression tasks or {−1, 1} for classification tasks)
and an hypothetical function f ∗ : X → Y which represents the best that anybody
could do when predicting the output from the input. This expression is understood
in the following sense. In order to model uncertainty, the relation between X and Y
is random. f ∗ is the prediction function that works the best on average.
In practice, one is given a training set of examples of size n, (xi, yi) ∈ X × Y ,
i = 1 . . . n, a function class F of functions X → Y and a loss function L : Y ×Y → R.
Many learning algorithms consist in solving
fˆ = argminf∈F
1
n
n∑
i=1
L(f(xi), yi) (2.4)
which is minimizing the risk evaluated on a finite sample. The theoretical properties
of this procedure is the object of study of statistical learning theory. For example,
using tools from empirical process theory, under restrictions on the function class
F , the empirical risk minimization procedure is shown to be consistent. This means
that when the problem is embedded in a probabilistic structure, as more and more
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data comes in, the empirical risk minimization procedure for certain function classes
provides an estimate fˆ which is close to the best estimate one could expect f ∗. [123]
provides detailed arguments as well as pointers to the literature. Practically, the
implication of these results are the following. If there exists a hypothetical true
function, the estimated function fˆ should be close to it, provided that enough data is
available. It can then be used in a prediction context to interpolate the information
contained in a training set to unseen examples.
2.2.2 Choice of the loss function
Different function classes and different loss functions define different estimators. The
loss function depends on the problem at hand. It should reflect how a given function
fits to the training set, and allow to solve the problem (2.4) efficiently. For example,
in the case of regression, the output space Y is a continuous subset of R. In this
case, the most popular loss function is the square loss Ls : (y1, y2) → (y1 − y2)2.
In binary classification tasks, the output space is binary, identified with {−1, 1}.
Popular loss functions in this context are the logistic loss Ll(y1, y2) = log(1 + e
−y1y2)
which defines logistic regression and the hinge loss of the support vector machine,
Lh(y1, y2) = (1 − y1y2)+ where (.)+ denotes the positive part. These losses are used
in chapters 3 and 4.
2.2.3 Kernels and kernel methods
The second aspect of the definition of an estimator in the framework of supervised
learning is to choose a function class. One of the simplest example is the class of
linear functions which are widely used in regression and classification. Kernels are
mathematical objects that have the same properties as an inner product. Positive
definite kernels have the appealing property that they allow to define classes of non
linear functions that are tractable in the sense that problem of the form of (2.4) can
be solved efficiently. They allow to perform learning with objects that cannot be
embedded in vector spaces, such as graphs or trees, and to generalize linear methods
to non linear settings. Moreover, they exhibit state-of-the-art performances on many
18 CHAPTER 2. METHODS
real world problems. Support vector machines involving kernel for molecules and
kernel regression are used in chapters 3 and 4. Many more details about positive
definite kernels and practical examples are found in [104]. The reproducing Hilbert
space theory describes how positive definite kernels define function classes. A detailed
exposition is found in [8].
2.2.4 Nearest neighbours
Given the training set (xi, yi) ∈ X × Y , when a distance is available on X , the
k-nearest neighbours methods consists in choosing as an estimate the function
fˆ : x ∈ X → 1
k
∑
xi∈Nk(x)
yi
where xi ∈ Nk(x) when xi is one of the k nearest neighbours of x, and k is a tuning
parameter. This constitutes a baseline method that is used in chapters 3 and 4 for
performance assessment.
2.3 Inference and learning in probabilistic models
This section presents algorithmic details related to the methods that are proposed in
chapters 4 and 5. Broadly speaking, inference is the task of computing expectations
and learning is the task of computing local optima under some probabilistic distribu-
tion. Despite the simplicity of the formulation, this turns out to be often intractable
on real world problems. Numerical approximations are required in many practical
cases. A first paragraph briefly presents the Expectation Maximization algorithm
which is used in chapter 4 and the second paragraph present Monte Carlo Sampling
Methods used in chapter 5. The presentations is brief and informal. The book [77]
provides details about probabilistic graphical models and inference methods and the
article [5] is a good introduction to sampling algorithm for probabilistic modelling.
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2.3.1 EM algorithm
This is a maximum likelihood procedure that allows to perform learning in generative
probabilistic models with partially observed data [27]. A generative model is the
definition of a generative stochastic process from which a dataset D is supposed to be
an independent identically distributed sample. In this paragraph, models with hidden
random variables are considered, denoted by Z. If θ ∈ Θ is a parameter belonging to
some space, a generative process defines a density function:
P (D, Z|θ).
This density function assigns a likelihood to the complete data (observed and non ob-
served) given the parameter. This is referred to as complete likelihood. Model fitting
consists in finding the parameter value θ∗ that maximizes the marginal likelihood:
P (D|θ) =
∑
Z
P (D, Z|θ).
The fact that some variables are not observed leads to intractable likelihood functions
in the sense that their evaluation are computationally very expensive. Indeed, the
size of the space in which the variable Z is embedded often grows exponentially with
the size of the dataset D. This is the case in clustering applications for example. The
EM algorithm is a local search method that is based on the following two steps
• Expectation step: Compute a tractable lower bound on the likelihood func-
tion. This is done by computing the expectation of the complete log likelihood
given the current parameters, integrating out the hidden variable Z.
• Maximization step: Find the parameters that maximize the expression com-
puted in the previous step.
Alternating these two steps allows to find a local maximum of the log likelihood func-
tion. This algorithm is used in chapter 4 for fitting the probabilistic model designed
for cell population phenotyping. This algorithm is one of the most simple instances of
variational inference methods which are widely used in probabilistic modelling [66].
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2.3.2 Markov Chain Monte Carlo and importance sampling
The Bayesian approach considers that the parameters of a model are random quanti-
ties. If one is given a likelihood function P (D|θ) where D is a dataset and θ is a vector
of parameters. In the Bayesian framework, one defines a prior distribution over the
parameter space π0(θ) and explores the posterior density which takes the form:
π1(θ|D) ∝ P (D|θ)π0(θ).
Inference under this density is often intractable analytically or even numerically. Sam-
pling methods are designed to sample from a probability distribution which can only
be evaluated up to a constant multiplicative factor, which is precisely the case here.
The main application is to approximate expectations of given functions based on this
sample. Suppose that we are exploring a space X endowed with a probability measure
P. Let {xi}ni=1 ∈ X n be an independent identically distributed sample from P. Given
a function f : X → R, one can approximate the expectation of f under P by:
∫
X
f(x)dP(x) ≃ 1
n
n∑
i=1
f(xi).
The convergence of the approximation to the true numerical value is guaranteed by
the strong law of large numbers. Now, suppose that one wishes to compute the
expectation of f under another probability distribution Q, one can use the same
sample to approximate this value numerically.
∫
X
f(x)dQ(x) ≃ 1∑n
i=1wi(x)
n∑
i=1
f(xi)wi(x).
Where wi(x) =
dP(x)
dQ(x)
. This estimate is biased but also converges to the true value as
the sample size grows. It is referred to as the importance sampling method. These
two methods are used in chapter 5 in the context of Bayesian inference and risk
estimation.
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In order for those methods to work, one needs to be able to sample from a prob-
ability distribution P. In chapter 5, we use a Markov Chain which elements can be
proven to be asymptotically distributed according to the distribution of interest. The
main sampling algorithm used is Metropolis Hasting which is the most famous Markov
Chain Monte Carlo sampling algorithm [11]. It consists in exploring the parameter
space based on a random walk guided by the distribution of interest, rejecting or
accepting random moves depending on this distribution. [5] is a good introduction
to sampling numerical approximation methods.
2.4 Empirical model evaluation and cross valida-
tion
Many aspects of this thesis relate to the evaluation of machine learning methods in
a biological context. By evaluation, we mean how well a method produces correct
predictions on an unseen dataset after being trained on a training set of known ex-
amples. The first method to empirically assess performance of a statistical procedure
is to test it on a synthetic dataset. This approach is used in chapter 5. Empirical
evaluation on real data would require to train a method on a training set, to acquire
a new dataset of the same kind and evaluate how well the method generalizes on this
new dataset. Cross validation mimics this process. V -fold cross validation consists
in partitioning a dataset in V parts of roughly equal size, train a method on V − 1
subsets and test it on the held out set. Repeating this procedure multiple times gives
an idea of the generalization performance of the method and provides clues about the
robustness of these performances. Chapter 7 in [51] provides more details about this
procedure. A historical and technical survey is available in [7].
Chapter 3
Protein-ligand interactions
Re´sume´
L’identification de re`gles sous-jacentes a` la reconnaissance entre les sous structures
chimiques d’un ligand et le site fonctionnel d’une prote´ine constitue un proble`me im-
portant pour la compre´hension des me´canismes conduisant a` des effets phe´notypiques
a` plus grande e´chelle. Ce chapitre se concentre sur l’identification de telles re`gles.
Nous de´crivons une me´thode nouvelle pour extraire des ensembles de sous structures
chimiques et de domaines prote´iques qui sous tendent les interactions prote´ine ligand
a` l’e´chelle du ge´nome. La me´thode est base´e sur l’analyse canonique des correspon-
dances parcimonieuse (SCCA) pour l’analyse conjointe de profils de sous structures
mole´culaires et de domaines prote´iques. Une approche par classification L1 pe´nalise´e
pour extraire des associations pre´dictives entre sous-structures et domaines prote´iques
est e´galement de´crite, et compare´e a` l’approche SCCA.
Les re´sultats expe´rimentaux sont base´s sur un jeu de donne´es d’interactions prote´ine-
ligand contenant des enzymes, des canaux ioniques, des re´cepteurs couple´s aux prote´ines
G et des re´cepteurs nucle´aires. La me´thode SCCA extrait des ensembles de sous
structures partage´es par des ligands qui peuvent se fixer a` un ensemble de do-
maines prote´iques. Ces deux ensembles de sous-structures chimiques et de domaines
prote´iques forment des composantes qui peuvent eˆtre exploite´es dans un cadre de
de´couverte de me´dicaments. Cette approche regroupe des domaines prote´iques qui
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ne sont pas ne´cessairement lie´s d’un point de vue e´volutif, mais qui partagent des lig-
ands pre´sentant des structures chimiques similaires. Plusieurs exemples montrent que
cette information peut eˆtre utile dans un cadre de pre´diction d’interaction prote´ine-
ligand ainsi que pour aborder le proble`me de la spe´cificite´ d’un ligand. Nous de´crivons
une comparaison nume´rique entre les deux me´thodes propose´es, SCCA et classifica-
tion L1 pe´nalise´e, ainsi que des me´thodes a` l’e´tat de l’art, sur la base du proble`me
de pre´diction d’interactions prote´ine-ligand. Ce chapitre se base principalement sur
l’article [137] et une partie des re´sultats pre´sente´s dans [118].
Abstract
The identification of rules governing molecular recognition between ligand chemical
substructures and protein functional sites is a challenging issue for the understanding
of molecular mechanisms driving larger scale phenotypic effects. This chapter focuses
on the identification of such rules. We describe novel methods to extract sets of
chemical substructures and protein domains that govern molecule-target interactions
on a genome-wide scale. The method is based on sparse canonical correspondence
analysis (SCCA) for analyzing molecular substructure profiles and protein domain
profiles simultaneously. An L1 penalized classification approach that extracts pre-
dictive associations between substructure and protein domains is also described, and
compared to the SCCA approach.
Experimental results are based on a dataset of known protein-ligand interactions
including enzymes, ion channels, G protein-coupled receptors and nuclear receptors.
SCCA extracts a set of chemical substructures shared by ligands able to bind to a set
of protein domains. These two sets of extracted chemical substructures and protein
domains form components that can be further exploited in a drug discovery process.
This approach successfully clusters protein domains that may be evolutionary unre-
lated, but that bind a common set of chemical substructures. As shown on several
examples, it can also be very helpful for predicting new protein-ligand interactions
and addressing the problem of ligand specificity. We describe a numerical comparison
between the two proposed methods, SCCA and L1 penalized supervised classification,
24 CHAPTER 3. PROTEIN-LIGAND INTERACTIONS
and state-of-the-art approaches based on supervised protein ligand interaction pre-
diction task. The chapter is mostly based on [137] and results from [118].
3.1 Introduction
3.1.1 Protein-ligand interactions
A ligand is a small chemical compounds which interferes with the biological behaviour
of its target proteins by direct physical interaction with it. These processes lead
to phenotypic effects observed at larger scale (cellular or even macroscopic scale).
For example, when a xenobiotic molecule binds to a protein, it perturbs the whole
interaction network of this protein, affecting many underlying biological processes.
In other words, the effect of a small molecule inside a living organism is the result of
the disturbance of all the biological processes which involve a protein to which the
molecule binds. It is therefore required to adopt a global point of view and consider
all potential targets at the same time when studying these phenomena .
Conventional approaches, such as QSAR and docking can handle only a single
protein at a time, and therefore, do not allow to adopt such a global point of view
and treat a large set of potential target proteins at a genomic scale. The results dis-
cussed in this chapter constitute a methodological contribution toward the adoption
of system approaches in the context of protein-ligand interaction predictions. A wide
scale of proteins and chemical compounds are considered and jointly analysed. The
main application of the approach is the design and optimization of drugs.
3.1.2 Existing approaches and motivations
A commonly used computational approach to analyze and predict ligand-protein in-
teractions is docking. Docking approaches consist in finding the preferred orientation
of a molecule binding to a protein by modelling the underlying physical energies (see
[76] for recent review). Therefore, docking cannot be applied to proteins with un-
known 3D structures. Moreover, docking protocols need to be tuned for each protein
target, which prevents its use on a large number of proteins at the same time. This
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limitation is critical in the case of membrane proteins such as G protein-coupled re-
ceptors (GPCRs) which are signal transduction pathway activators, or ion channels
which shape electrical signals. Indeed, these membrane proteins are difficult to ex-
press, purify and crystallise. Although being both major therapeutic targets, their
3D structure is known to be particularly difficult to determine.
In this context, the importance of chemogenomic approach has grown fast in
recent years [67, 117, 28], and a variety of statistical methods based on chemical and
genomic information have been proposed to predict drug-target or more generally,
ligand-protein interactions. These methods assume that similar proteins bind similar
ligands. This assumption is often verified in practical cases and allows to predict
protein-ligand interactions for new chemical compounds and new proteins. These
methods differ by the underlying description used for proteins and ligands, and by
how similarities between these objects are measured. Examples are statistic-based
methods that compare target proteins by the similarity of the ligands that bind to
them, which can then be used to predict new protein-ligand interactions [46, 70].
Other approaches are the binary classification approaches such as support vector
machine with pairwise kernels for compound-protein pairs [86, 33, 59] which we use
as a state-of-the-art comparison point in this chapter, and the supervised bipartite
graph inference with distance learning based on chemical and genomic similarities
[134, 133].
Ligand-protein interactions are often due to the presence of common chemical
structures (the pharmacophore) that are usually shared by the ligands of a given
protein, whereas this is not expected for random compounds that do not bind to the
same protein. Recently, a variety of analyses have been conducted, such as analysis
of chemical substructures and biological activity [75], data mining of chemical struc-
tural fingerprints and high-throughput screening data in PubChem [50], or extraction
of chemical modification patterns in drug development [108]. Ligand-protein inter-
actions are also due to functional sites of proteins (e.g., binding pockets, domains,
motifs). Recently, the comparison of binding pockets has been done to investigate
the relationship with their ligands [85, 87, 53]. However, these methods require the
availability of the 3D structure of proteins. To date, most of the research has been
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performed separately from the viewpoints of either ligands or proteins. Yet, the rel-
evant question is how to relate ligand chemical substructures with protein functional
sites in terms of ligand-protein interactions. There is therefore a strong incentive to
conduct an integrative analysis of both ligand substructures and protein functional
sites toward understanding of ligand-protein interactions. In this domain, a challeng-
ing issue is to develop methods that identify rules for molecular recognition between
ligand chemical substructures and protein functional sites. The proposed methods
tackle this problem based on co-occurrences of protein domains and molecular sub-
structures in interacting and non-interacting protein-molecule pairs.
3.1.3 Content of the chapter
In this chapter, we describe two novel methods to extract sets of drug chemical sub-
structures and protein domains that govern drug-target interactions. The first one
is based on canonical correspondence analysis (CCA) for analyzing drug substruc-
ture profiles and protein domain profiles simultaneously. We develop an extension of
the CCA algorithm by incorporating sparsity for easier interpretation, which we call
sparse canonical correspondence analysis (SCCA). Figure 3.1 shows an illustration of
the proposed method. The main interest and originality of the proposed method is
that it correlates protein domains to chemical substructures expected to be present in
their ligands, based on a learning dataset. From a system point of view, one strength
of the method is that it allows to analyse jointly the interactions of many proteins
and many molecules. This allows to point out interaction patterns that would not
have been foreseen by looking at each interaction separately. Examples illustrate
the fact that the method identifies pharmacophores automatically, thus providing
structural insights about the mechanisms that govern molecular recognition. These
pharcophores are shared by common ligands of a protein. Beyond the protein-ligand
interaction problem, the examples we provide illustrate the benefits of system based
approach when mining large interaction networks involving many chemical species.
This work is based on the article [137].
An extension of this work leads to another method to tackle the same problem. It
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uses an explicit representation of the tensor product space of possible pairs of molec-
ular substructure and protein domain together with L1-regularized linear support
vector machine. This method is referred to as L1-PLSVM and also extracts pairs of
protein domains and chemical substructures that explain protein target interactions.
This constitutes a sub-part of the results presented in [118]. Most of the content of
the chapter is dedicated to SCCA method, but a comparison between L1-PLSVM
and SCCA is made based on their prediction performances.
We first describe the dataset that has been used to conduct those experiments.
Then the different methods are presented as well as a description of the numerical
experiments that allow to compare different methods from a supervised learning point
of view. We compare to the reconstruction performances of a baseline and a state-of-
the-art method designed for similar tasks. Biological examples illustrate the ability of
the SCCA method to point out meaningful insights when treated as an unsupervised
method. Numerical results highlight the different scenarios for which SCCA or L1-
PLSVM provide the best of their performances.
3.2 Materials
Drug-target interactions were obtained from the DrugBank database which combines
detailed data about drugs and drug candidates with comprehensive drug-target in-
formation [128]. The version of DrugBank is 2.5. Proteins belong to many different
classes, among others, pharmaceutically useful ones such as enzymes, ion channels, G
protein-coupled receptors (GPCRs) or nuclear receptors. In this study, we focused on
human proteins, which drove us to select all interactions involving human proteins.
This led to build a protein-drug dataset containing 4809 interactions involving 1554
proteins and 1862 drugs. The set of interactions is used as gold standard data.
To encode the chemical structures of drugs involved in these interactions, we used
a fingerprint corresponding to the 881 chemical substructures defined in the PubChem
database [22]. Each drug was represented by an 881 dimensional binary vector whose
elements encode for the presence or absence of each PubChem substructure by 1 or 0,
respectively. Most of the drugs documented in DrugBank have a link to PubChem,
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Figure 3.1: An illustration of the proposed method.
but some do not, mainly biotech drugs and mixtures. Interactions involving drugs
that have a record in PubChem were kept. Among the 881 substructures used to
represent the chemical structures, 663 are actually used, because 218 do not appear
in our drug set.
For all proteins, genomic information and annotation were obtained from the
UniProt database [6], and associated protein domains were obtained from the PFAM
database [35]. PFAM database gathers a large number of protein functional domains.
They are regions of the amino acid sequence that are associated with a specific molec-
ular function (e.g. recognising site of an enzyme that catalyses a chemical reaction).
A protein might have several domains related to several functions which allow to
recognize several molecules. These domains implicitly represent proteins by their
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functions. In the set of proteins we took into account, 876 PFAM domains are found.
Therefore, each protein was represented by a 876 dimensional binary vector whose
elements encode for the presence or absence of each of the retained PFAM domain
by 1 or 0, respectively.
3.3 Methods
We want to extract drug chemical substructures and protein domains which tend to
jointly appear in the interacting pairs of drugs and target proteins, and to disappear
in the other pairs. This section recalls methods mentioned in chapter 2 and describe
how they are adapted in the context of drug target interaction prediction.
3.3.1 Sparse canonical correspondence analysis (SCCA)
Suppose that we have a set of nx drugs with p substructure features, a set of ny target
proteins with q domain features, and information about interactions between the drug
set and the target protein set. Note that nx 6= ny. Each drug is represented by a
p-dimensional feature vector x = (x1, · · · , xp)T , and each target protein is represented
by a q-dimensional feature vector y = (y1, · · · , yq)T .
Consider two linear combinations for drugs substructure and proteins domains as
ui = α
Txi (i = 1, 2, · · · , nx) and vj = βTyj (j = 1, 2, · · · , ny), respectively, where
α = (α1, · · · , αp)T and β = (β1, · · · , βq)T are weight vectors. Define the nx × ny
adjacency matrix A, where element (A)ij is equal to 1 (resp. 0) if drug xi and
protein yj are interact (resp. do not interact). Let X be the nx× p matrix defined as
X = [x1, · · · ,xnx ]T , and let Y denote the ny×q matrix defined as Y =
[
y1, · · · ,yny
]T
,
where the columns ofX and Y are assumed to be centered and scaled. As described in
chapter 2, SCCA consists in finding weight vectors α and β which solve the following
L1 constrained optimization problem:
max{αTXTAY β} subject to
||α||22 ≤ 1, ||β||22 ≤ 1, ||α||1 ≤ c1
√
p, ||β||1 ≤ c2√q, (3.1)
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where || · ||1 is L1 norm (the sum of absolute values of vector entries), c1 and c2 are
parameters to control the sparsity and restricted to ranges 0 < c1 ≤ 1 and 0 < c2 ≤ 1,
where c1 = c2 = 1 defines the original CCA (OCCA) without sparsity constraint and
amounts to compute an SVD (see chapter 2).
Problem (3.1) can be regarded as the problem of penalized matrix decomposition
of the matrix Z = XTAY . As mentioned in chapter 2, we can use the penalized
matrix decomposition (PMD) proposed by [129]. After m iterations of the algorithm,
we obtain m pairs of weight vectors α1, · · · ,αm and β1, · · · ,βm which are referred
to as components. Components of lower k are called “lower order components”,
while components of higher k are called “higher order components”. High scoring
substructures and domains in the weight vectors are considered important in terms
of drug-target interactions.
The originality of the SCCA method lies in the development of a sparse version
of canonical correspondence analysis to handle the heterogeneous objects and their
co-occurence information. It is therefore impossible to directly apply the canonical
correlation analysis or its sparse version [93, 124, 129] in the question addressed here.
3.3.2 Evaluation of extracted components by reconstruction
of drug-target interactions
If the extracted components are biologically meaningful, their use to reconstruct
known drug-target interactions should lead to good prediction accuracies. Given
a pair of compound x and protein y, their potential interaction can be estimated
based on the chemical substructures present in x, the protein domains present in y,
their presence in common extracted components, and their distribution over all the
canonical components. We use the following prediction score described in chapter 2.
For any given pair of compound x and protein y:
s(x,y) =
m∑
k=1
ukρkvk =
m∑
k=1
xTαkρkβ
T
k y, (3.2)
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where m is the number of canonical components and ρk is the k-th singular value. If
s(x,y) is higher than a threshold, compound x and protein y are predicted to interact
with each other.
We perform the following 5-fold cross-validation to evaluate the reconstruction
ability. 1) We split drugs and target proteins in the gold standard set into five
subsets of roughly equal sizes, and take each subset in turn as a test set. 2) We
perform the training of CCA model on the remaining four sets (i.e. we extracted
canonical components based on the remaining four sets). 3) We compute the above
prediction score for the test set, based on the components extracted from the training
set. 4) Finally, we evaluate the prediction accuracy over the five folds.
3.3.3 Supervised methods to reconstruct drug-target inter-
actions
Pairewise Support Vector Machine has shown state-of-the-art performances on such
supervised tasks. The L1-penalized linear SVM is an instance of this specific approach
which associates pairs of features that have a highly predictive power. Nearest neigh-
bour is used as a baseline. For all methods, we used the same representations for
proteins and ligands, i.e. the feature vectors described in the Materials section 3.2.
Pairwise support vector machine (P-SVM and L1-PLSVM)
The SVM is a well-known binary classifier, and it is becoming a popular classifica-
tion method in bioinformatics and chemoinformatics because of its high-performance
prediction ability [105]. The use of SVM with pairwise kernels have been proposed
to predict new compound-protein interactions [86, 33, 59], which is referred to as
pairwise SVM (P-SVM). The pairwise SVM approach reduces the task of predicting
interactions to a binary classification task. We consider a training set of drug target
pairs (xi,yi, ii)i=1...n where xi is a drug, yi is a protein represented by their p and
q dimensional feature vectors respectively and ii is a class variable corresponding to
the interaction of drug xi and protein yi. Given Kd and Kp, positive definite kernels
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for drugs and proteins respectively, the function:
K((x1,y1), (x2,y2)) = Kd(x1,x2)Kp(y1,y2)
is a positive definite kernel on pairs of drug protein pairs. Standard supervise learning
methods can be applied to discriminate between interacting and non interacting pairs.
Applying an SVM to this problem using such a pairwise kernel defines the pairwise
SVM. We tested several kernel functions such as linear kernel, Gaussian RBF kernel
with various width parameters, polynomial kernel with various degree parameters
for drug substructure profiles and protein domain profiles, and the regularization
parameter. Those parameters are chosen by cross validation and the corresponding
best choices are reported in the result section.
When considering linear kernels, i.e. standard scalar product, the proposed kernel
between pairs implicitly corresponds to the scalar product between tensor product
representations of the protein target pairs. Indeed, in this case:
K((x1,y1), (x2,y2)) = x
T
1 x2y
T
2 y1 = Tr((x1y
T
1 )
Tx2y
T
2 )
where Tr denotes the trace operator for matrices. In this case K is the scalar product
between the matrices x1y
T
1 and x2y
T
2 which represent both pairs of protein targets.
They are binary matrices which represent the presence or absence of all possible
(substructure, domain) pairs. This representation is very high dimensional (663×876)
but also very sparse. Solving a linear SVM with such a representation amounts to
find a weight matrix w of the same size that minimizes the empirical loss LSVM (see
chapter 2 for details). By adding an L1 sparsity inducing term, we enforce sparsity
of the corresponding weights. This is referred to as the L1-PLSVM which explicitly
compute the tensor product representation behind the pairwise SVM and solves an
L1 penalized empirical risk minimization problem. As mentioned, the problem is
very high dimensional and very sparse. Specific libraries have been designed to take
advantage of such a structure [57] which allows to estimate a sparse matrix w using
this method in a reasonable time. The resulting estimate represents all possible all
possible (substructure, domain) pairs. Because we enforce sparsity, only a few of
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these entries are non zero. Thus this extension of the pairwise SVM allows to extract
association between chemical substructures and protein domains. However, these
pairs are not structured in canonical components as in the SCCA case.
Nearest neighbour (NN)
The classical nearest neighbour (NN) method is often used in molecular screening.
The proteins potentially interacting with a newly given compound x are determined
as those that interact with the most similar compound in the training set. Given a
new compound x, we find x′, its nearest neighbour in the training data according
to the fingerprint profile similarity and predict the proteins interacting with x′ to
interact with x with a score reflecting the similarity between x and x′. Likewise,
potential ligands for a newly given protein y are determined as those that bind to
the most similar protein in the training set. Given a new protein y, we find y′, its
nearest neighbour in the training data according to the domain profile similarity and
predict the molecules interacting with y′ to interact with y with a score reflecting the
similarity between y and y′. The cosine correlation coefficient is used as a similarity
measure for both compounds and proteins.
3.4 Results
3.4.1 Performance evaluation for the SCCA method
In general, it is difficult to evaluate the performance of an unsupervised feature ex-
traction method in a direct manner. However, if the extracted sets of chemical sub-
structures and proteins domains (the components) are biologically meaningful and
capture relevant information with respect to protein-ligand interactions, one would
expect that they present good generalization properties. This can be evaluated by
testing the ability of the method to reconstruct known drug-target interactions, using
the prediction score and the five fold cross-validation scheme described in section 3.3.
We evaluated the performance of the method by the ROC (receiver operating
characteristic) curve [48], which is the plot of true positives as a function of false
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Table 3.1: Performance evaluation on drug-target interactions reconstruction by 5-
fold cross-validation.
NN P-SVM L1-PLSVM OCCA SCCA
AUC 0.5892 0.7504 0.7061 0.7377 0.7497
S.D. 0.0042 0.0064 0.0015 0.0046 0.0057
positives based on various thresholds, where true positives are correctly predicted
interactions and false positives are predicted interactions that are not present in the
gold standard interactions. We summarized the performance by an AUC (area under
the ROC curve) score, which is 1 for a perfect inference and 0.5 for a random inference.
We repeated the cross-validation experiment five times, and computed the average of
the AUC scores over the five cross-validation folds, varying the three parameters of
the method. The best results were obtained with c1 = 0.1, c2 = 0.2 for the sparsity
parameters, and with m = 50 for the number of components in the case of SCCA.
The same experiments were repeated for OCCA which has only one parameter, and
the best results were obtained for m = 50.
The AUC scores for SCCA and OCCA are 0.7497 and 0.7377, respectively. These
statistics are summarized in table 3.1. This result shows that both methods perform
much better than a random inference, whose AUC score is equal to 0.5. Consequently,
this indicates that the proposed prediction score allows to enlighten the good gen-
eralization properties of extracted SCCA or OCCA components. Their performance
comparison with other methods will be discussed in a later subsection.
Next, we applied SCCA and OCCA on the complete gold standard dataset de-
scribed in the Materials section, and analyzed the extracted components of drug
chemical substructures and protein domains. We used the parameters leading to the
best results in the cross-validation experiment.
We examined the resulting weight vectors for drug chemical substructures and
protein domains in applying OCCA and SCCA. Figure 3.2 shows the index-plot of
weight vectors in applying OCCA, while figure 4.3 shows the index-plot of weight
vectors in applying SCCA, where the first six canonical components are shown in
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Figure 3.2: Index-plot of weight vectors for drug substructures and protein domains
for OCCA. Horizontal axes indicate the index of chemical substructures (upper) or
protein domains (bottom), and vertical axes indicate the weight values on the chemical
substructures (upper) or protein domains (bottom).
both cases. It seems that almost all elements in the weight vectors in OCCA are non-
zero and highly variable, while most of the elements in the weight vectors in SCCA
are zero in each component, implying that SCCA can select a very small number of
features as informative drug substructures and protein domains.
These results suggest that, although the performance in reconstruction of drug-
target interactions of SCCA and OCCA were close, the proposed SCCA provides us
with more selective drug substructures and protein domains, without missing impor-
tant information encoding protein-ligand interaction. In practice, we found that it is
very difficult to analyze the extracted components when there are too many high or
low scoring weight elements like in OCCA. On the contrary, the advantage of SCCA
over OCCA is that it is possible to derive biological interpretations, as shown on a
few examples in the next subsection.
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Figure 3.3: Index-plot of weight vectors for drug substructures and protein domains
for SCCA. Horizontal axes indicate the index of chemical substructures (upper) or
protein domains (bottom), and vertical axes indicate the weight values on the chemical
substructures (upper) or protein domains (bottom).
3.4.2 Comparison with other supervised methods
If the proposed method captures important features that govern protein-ligand inter-
actions, and if the proposed prediction score is relevant, the performance should be
at least as good as those of other methods for predicting protein-ligand interactions,
using the same vector descriptions for proteins and ligands.
We performed the same five-fold cross validation experiments for the three other
considered prediction methods NN, P-SVM and L1-PLSVM on the same protein-
ligand dataset, as we did for SCCA and OCCA. The best performance was obtained
using the polynomial kernel with degree parameter d = 3 and the regularization
parameter C = 1 in the case of P-SVM .
Table 3.1 shows that SCCA, OCCA and L1-PLSVM outperform the baseline,
i.e. the NN. Furthermore, the performance of SCCA is similar to that of P-SVM
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Figure 3.4: Execution time for different methods on a log scale. The pairwise SVM
is the most computationally intensive method by at least one order of magnitude.
used as the state-of-the-art prediction method. Performances of L1-PLSVM are a bit
lower but still much better than NN. These results show that the extracted canonical
components contain valuable biological information and underline the interest of the
proposed method as a tool for analyzing protein-ligand interactions. In addition, it
should be pointed out that P-SVM and NN do not provide any biological interpre-
tation since they only predict interactions, and they do not extract any information
about important molecular features for these interactions.
We also investigated the computational cost for each method. Figure 3.4 shows
the total execution time of the cross-validation experiment between the four different
methods. NN is the fastest, followed by OCCA, SCCA, and P-SVM. As expected, P-
SVM is much slower than the other methods, because the complexity of the “learning”
phase scales with the square of the “number of training compounds times the number
of training proteins”, leading to prohibitive computational difficulties for large-scale
problems. These results suggest that SCCA constitutes a good trade-off between
prediction accuracy, biological interpretation, and computational efficiency.
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3.4.3 Biological interpretation of extracted drug substruc-
tures and protein domains using SCCA
The SCCA method provides 50 canonical components. The output of the method
is a list of canonical components (CCs), each of which contains correlated chemical
substructures and protein domains, and a list of proteins and drugs that contributed
to extract the chemical substructures and protein domains. All components present a
limited number of high scoring chemical substructures and protein domains, which is
a consequence of the sparsity of the method. It extracts domains and substructures
that summarize the most relevant and consistent information. This allows meaningful
analysis of the data for biological interpretation. Table 3.2 shows some examples
of extracted chemical substructures (SMILE-like format in PubChem) and protein
domains (PFAM IDs) in the first four CCs (CC1, CC2, CC3 and CC4).
We examined the extracted drug substructures and protein domains from bio-
logical viewpoints. The results for a few canonical components will be discussed.
Analysis of the results shows that the components contain a limited number high
scoring protein domains that usually belong to one, or a small number of protein
families. For example, most high scoring protein domains of component CC1 be-
long to nuclear receptors (PF02159: Oestrogen receptor, PF02155: Glucocorticoid
receptor, PF00104: Ligand-binding domain of nuclear hormone receptor, PF02161:
Progesterone receptor, PF02166: Androgen receptor, PF00105 zinc finger c4 type).
Consistent with this observation, the high scoring substructures are typical fragments
found in steroids, and the high scoring drugs are steroid-like molecules. The domains
from nuclear receptors also appear with high scores in a few other components such
as CC4 or CC12. However, these components do not share any of their high scoring
chemical substructures, which shows that they are not redundant. We observed that
the absence of redundancy between components is a general feature of the method.
Unexpectedly, the annexin domain PF00191 is also present in the top ranked do-
mains of CC1. Annexins are membrane associated proteins that bind phospholipids,
inhibit the activity of phospholipase A2, and play a role in the inflammatory response.
Annexins and nuclear receptors are evolutionary unrelated proteins with no sequence
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Table 3.2: Examples of results for canonical components 1, 2, 3 and 4: high scoring
domains, substructures, proteins and drugs
Domain PF02159 (Oestrogen receptor); PF02155 (Glucocorticoid receptor);
PF00191 (Annexin); . . .
Structure CC1CC(O)CC1; CC1C(O)CCC1; saturated or aromatic carbon-only ring size 9;
CC1C(C)CCC1; . . .
Protein ESR1 HUMAN (Estrogen receptor);
GCR HUMAN (Glucocorticoid receptor); . . .
Drug DB00443 (Betamethasone); DB00823 (Ethynodiol Diacetate);
DB00663 (Flumethasone Pivalate)); . . .
Domain PF00194 (Carbonic anhydrase); PF08403;
PF02254; PF03493 (potassium channel);. . .
Structure SC1CC(S)CCC1; Sc1cc(S)ccc1; Sc1c(Cl)cccc1;
SC1C(Cl)CCCC1; N-S-C:C; N-S; . . .
Protein KCMA1 HUMAN (Calcium-activated potassium channel);
CAH12 HUMAN (Carbonic anhydrase 12); . . .
Drug DB00562 (benzthiazide); DB00232 (Methyclothiazide);
DB01324 (Polythiazide); . . .
Domain PPF00001 (transmembrane receptor);
PF03491 (Serotonin neurotransmitter transporter); . . .
Structure C( H)(:C)(:C); C:C-C-C; C-C-C-C:C; C:C-C-C-C;
C-C:C-C-C; C-C-C:C-C; . . .
Protein TOP2A HUMAN (DNA topoisomerase);
SC6A4 HUMAN (Sodium-dependent serotonin transporter); . . .
Drug DB01654 (Thiorphan); DB00743 (gadobenic acid);
DB03788 (GC-24); . . .
Domain PF00105 (Zinc finger); PF00104; PF02159 (Oestrogen receptor);
PF00191 (Annexin); . . .
Structure C( C)( C)( C)( C); C-C(C)(C)-C-C;
unsaturated non-aromatic carbon-only ring size 6; . . .
Protein ESR1 HUMAN (Estrogen receptor);
GCR HUMAN (Glucocorticoid receptor); . . .
Drug DB00596 (halobetasol); DB01234 (Dexamethasone);
DB00620 (Triamcinolone); . . .
or function similarities. However, annexins and nuclear receptors probably present
similar ligand binding pockets in the 3D space, which could not be foreseen from com-
parison of their primary sequences, and both types of proteins can bind steroid-like
ligands. Therefore, the method associated these protein domains in CC1. Some of
these steroids ligands are common to both types of proteins. For example DB00443
and DB00663 (respectively PubChem IDs 9782 and 443980) bind to glucocorticoid
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receptor and to annexin A1. On the contrary, some steroids only bind to a nuclear
receptor and not to annexin. This observation suggests that the method might offer
a tool to tackle the important question of specificity
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Figure 3.5: (A) Examples of high scoring substructures from components CC1 and
CC4 belonging to group A. (B) In blue, part of the molecular structure of DB00823
that can be built using high scoring substructures of components of group A. In red,
part of DB00823 that can be built using high scoring substructures of components of
group B (specific of estrogen receptor). (C) In blue, part of the molecular structure of
DB01013 that can be built using high scoring substructures of components of group
A. In red, part of DB01013 that can be built using high scoring substructures of
components of group C (specific of annexin). In the case of SUB706, only chemical
groups that cannot be built using substructures of group A are colored in red.
To illustrate this point, we will consider the example of the estrogen receptor
ESR1 HUMAN (UniProt ID: P03372, Pfam IDs PF00104, PF00105, PF02159) and of
annexin A1 ANXA1 HUMAN (UniProt ID: P04083, Pfam ID PF00191). Domains of
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these two proteins have high weights in a few common components (CC1, CC4, CC13,
CC46, called group A), while only domains of estrogen receptors have high scores in
components CC12, CC15, CC29, CC34, CC38 (called group B), and only those of
annexin have high scores in components CC19, CC20, CC21, CC26, CC40 (called
group C). We will show in the case of drug DB00823 (or PubChem ID 9270) that binds
the estrogen receptor but not annexin, and of DB01013 (or PubCHem ID 32798) that
binds to annexin but not to the estrogen receptor, how analysis of the substructures
belonging to groups A, B and C can be used to explain the specificity of these two
drugs. The parts of the chemical structure of DB00823 and DB01013 that can be
built using high scoring substructures belonging to group A (components common to
estrogen receptor and annexin) is colored in blue in figure 3.5. They correspond to the
main steroid scaffolds of these two molecules, as expected for proteins sharing similar
types of ligands. However, additional chemical structures of the DB00823 molecule,
colored in red in figure 3.5, can only be built by using high scoring substructures
found in components of group B, where only estrogen receptor domains have high
scores. Similarly, additional chemical structures of DB01013, colored in red in figure
3.5, can only be built using high scoring substructures found in components of group
C, where only annexin domains have high scrores. Note that none of the high scoring
substructures of components specific of estrogen receptor (group B) are present in
DB01013 that only bind annexin, and that reciprocally, none of the high scoring
substructures of components specific of annexin (group C) are present in DB00823
that only bind estrogen receptor. In other words, the method allows to highlight
the parts of the molecules that encode for their specificity to bind only to estrogen
receptor, or only to annexin.
One additional comment should be made: all known annexin ligands are steroids,
while estrogen receptor domains also bind other types of molecules such as Tamoxifen
(DB00675, PubChem ID 2733526) or other similar molecules such as Raloxifen. As
shown in figure 3.6, these molecules are very different from steroids. They lead to the
CC34 and CC38 above mentioned components, that have a high score for estrogen
receptor domains and not for annexin domains because the latter do not bind these
molecules. In figure 3.6, the part of the Tamoxifen molecule that can be built using
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Figure 3.6: Chemical structure of Tamoxifen (DB00675). Parts of the molecule that
can be built from chemical substructures of components CC34 and CC38 are colored
in blue.
high scoring substructures from CC34 and CC38 is colored in blue.
We will comment more briefly on component CC2, in order to show that the
above observations also apply to other components and families of proteins. Compo-
nent CC2 contains the carbonic anhydrase domain PF00194 , which belongs to zinc
metalloenzymes catalyzing reversible hydration of carbon dioxide to bicarbonate. It
also contains calcium-dependent potassium channel domains (PF03493, PF02254).
Carbonic anhydrase inhibitors are used as anti-glaucoma agents, diuretics and anti-
epileptics. Interestingly, the human potassium channel KCMA1 HUMAN (UnitProt
ID: Q12791), one of the high scoring proteins in CC2, is also known to be involved
in epilepsy. Domains of the carbonic anhydrase and of the calcium-dependent potas-
sium channel also appear together with high scores in a few other components (namely
CC7, CC16, CC22, CC27 and CC43), whereas components CC3 and CC25 are spe-
cific of carbonic anhydrase, and component CC20 is specific of calcium-dependent
potassium channel.
Although different types of drugs are known to bind human calcium-dependent
potassium channel and carbonic anhydrase proteins, these two proteins share drugs
from the thiazide family. Figure 3.7 shows the general scaffold of thiazide molecules.
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Figure 3.7: (A) In blue, examples of high scoring substructures of components com-
mon to calcium-dependent potassium channel and carbonic anhydrase proteins. In
red, example of a high scoring substructure from component CC20 specific to calcium-
dependent potassium channel. (B) On the left, in black, the basic thiazide scaffold.
On the right, in blue, part of the molecular structure of DB00232 that can be built
using high scoring substructures from components common to calcium-dependent
potassium channel and carbonic anhydrase proteins. In red, part of DB00232 that
can be built using high scoring substructures of components CC20, specific of calcium-
dependent potassium channel.
All known thiazide ligands of carbonic anhydrase also bind calcium-dependent potas-
sium channel (for example DB00436 or DB00562, among others). However, the thi-
azide molecule DB00232 (PubChem ID 4121) only binds to KCMA1 HUMAN, the
human calcium-dependent potassium channel and not to human carbonic anhydrase.
As in the case of annexins and nuclear receptors, although carbonic anhydrase and
potassium channel present no sequence similarity, they share similar ligand binding
pockets, and are able to bind similar molecules. Therefore, the method associates
them in CC2 and in a few other common components, namely CC7, CC16, CC22,
CC27, CC43. In figure 3.7, the part of the DB00232 molecule that can be built using
substructures of these components is colored in blue. However, the calcium-dependent
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potassium channel domains have high scores in component CC20, but this is not the
case of carbonic anhydrase. In figure 3.7, the part of DB00232 that can only be built
using substructures of CC20 is colored in red. As in the case of estrogen receptor and
annexin, the method allows to highlight the parts of the DB00232 that encode for
its specificity to bind to calcium-dependent potassium channel and not to carbonic
anhydrase.
Finally, we would like mention that component CC20 appears in the two cases
discussed above, because the presence of SUB344 in steroid or thiazide molecules
happens to modulate their specificity, respectively for annexin or calcium-dependent
channel. The fact that a molecule contains substructure SUB344 does not necessarily
mean that it will bind to all high scoring proteins of CC20. Indeed, more generally,
the protein binding profile of a molecule depends on its complete substructure profile
which is not limited to an individual substructure.
3.4.4 Comments on L1-PLSVM method
Performances
The cross validation results presented in the previous paragraphs correspond to a
block wise split of the training and test set (see figure 3.8 for a graphical illustration).
This choice of validation is closer to reality than choosing the training pairs uniformly.
Indeed, in field applications, one is interested by finding candidate drugs for a given
protein or by finding targets for a given drug. However, this corresponds to a split
that is not uniform over all possible pairs but follows the structure of the matrix and
supervised learning method suffer from this bias. Indeed, the underlying assumption
behind the supervised learning framework is that the training examples are taken
uniformly at random from the space of possible examples (see chapter 2 for a brief
overview). Table 3.3 shows the cross validation results in a pairwise setting. In this
setting, the performance of the L1-PLSVM method are close to those of the P-SVM
method and significantly higher than those of SCCA. In such a setting, if the interest
is in reconstruction performances, such binary classification approaches should be
preferred.
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Table 3.3: Performance evaluation on drug-target interaction reconstruction by 5-fold
cross-validation in a pairwise setting.
L1-P-LSVM P-SVM SCCA
AUC 0.8301 0.8339 0.7975
S.D. 0.0006 0.0005 0.0018
1: Pair−wise 2: Block−wise
Molecules
Pr
ot
ei
ns Set
Test
Train
Figure 3.8: Illustration of pair-wise and block-wise cross validation. In the former
case, randomly selected pairs are used as a training set while in the latter, the training
and test sets reflect the row and column structure of the interaction matrix.
Extracted substructure domain pairs
Extracted pairs of substructure and domains using the L1-PLSVM method are con-
sistent with the underlying biology. This means that they are found in molecules
and proteins that indeed interact. However, these associations are not organized in
components as for the SCCA method. It is therefore more difficult to discuss deeper
examples of associations between chemical substructures and protein domains using
this method. It should be noted that the L1-PLSVM method extracts a smaller num-
ber of associated substructures and domains compared to SCCA (around two order
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of magnitude smaller).
It appears that the interest of the two methods depend on the focus point (su-
pervised reconstruction or unsupervised feature extraction) and the learning setting
(pair wise or block wise). Unsupervised feature extraction abilities of SCCA are of
greater interest. However it does not perform as well on reconstruction task in the
pair wise supervised setting. The results presented here shed light on which method
should be preferred depending on those parameters.
3.5 Discussion and Conclusion
In this chapter we described methods to extract drug chemical substructures and pro-
tein domains that govern drug-target interactions. The methods use known protein-
ligand interactions as a learning dataset to extract ligand substructures and their
associated protein domains, and importantly, they do not require information about
proteins 3D structures. From a system point of view, they provide integrative analysis
tools to study interactions between chemical and genomic spaces in a unified frame-
work. Since the methods can handle learning datasets containing many proteins
and molecules they constitute a contribution to the development of system based
approaches for protein-ligand interaction.
Quantitative structure-activity relationship (QSAR) methods are similar in spirit,
but they are designed handle a single protein at a time. The approach consists in using
molecular similarities to predict activity of new molecule against a given target based
on classification or regression methods. Such an approach cannot take advantage
of emerging information from large protein target interaction datasets at a genome-
wide level. Similar comments can be made regarding docking strategies which rely on
known 3D structure of proteins. Moreover, even for proteins of known 3D structures,
it is extremely difficult to automate the set-up of these methods for many different
binding sites, leading to docking and scoring inaccuracies when they are used on large
scale [71].
Prediction of all protein targets for a molecule is the goal of chemogenomics. Var-
ious studies report algorithms that implement such methods, and up to now, they
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have restrained the search of off-targets within a given family of proteins such as
GPCRs [126, 58, 135]. Nonetheless, they demonstrate the advantage of the approach
over QSAR like methods. The proposed method is a new contribution to the field of
chemogenomics which relies on learning databases of known protein-ligand interac-
tions and which can take into account evolutionary unrelated proteins.
3.5.1 Applications of SCCA in drug development
The method could be of interest in various ways in the drug development process.
First, given protein target of therapeutic interest, one can identify the components
into which this protein domains are found with high scores. Then, one can build a
ligand for this target protein using high scoring substructures of these components,
potentially with the help of other recent developments in the domain of fragment-
based drug discovery [31]. For example, in the Results section, we showed for several
drugs (DB00823, DB01013, DB00675, DB00232), that one could build their molecu-
lar structure using high scoring substructures of components in which their protein
targets have a high score.
Second, for a given drug that binds to a protein target of interest, the method
can help to identify off-target proteins: protein domains that are found with high
scores in the same components as these of the protein of interest are potential off-
targets. Trivial off-targets are proteins that share high sequence similarity with the
target protein, and are otherwise easy to identify using classical algorithms such as
BLAST [3]. However, two unrelated proteins that underwent convergent evolution
may present similar pockets in the 3D space, allowing binding of similar ligands,
although they may share no significant sequence similarity. The proposed method
can handle such cases by learning ligand similarities from a database. Examples
are shown in the Result section for estrogen receptor and annexin, or for calcium-
dependent potassium channel and carbonic anhydrase. Various methods have been
developed to predict protein-ligand interactions, but predicting off-targets for a drug
has been much less studied. The use of drug side-effect similarity has been proposed to
identify potential off-targets, but the method can therefore only be used for molecules
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of known side-effect profile, i.e. mainly for marketed drugs [20].
Finally, the method can also help to tackle the problem of drug specificity, which
is in fact related to the topic of off-target identification. Here, we are interested in a
given drug developed against a given target. The drug happens to also bind some off-
target proteins. The method could help to optimize the structure of this drug. The
principle would be to add chemical substructures that have high scores in components
where only the target protein has a high score, and not the off-target proteins. As
shown in section 3.4 for estrogen receptor and annexin, drugs that bind only one of
these proteins contain substructures present in components where only one of these
two proteins has a high score. The same situation was shown for DB00232 that only
bind calcium-dependent potassium channel, and not carbonic anhydrase. As shown
in section 3.4, the proposed method allows to identify such cases: non trivial off-
targets are expected to appear in the same components as the main target. Among
several drug candidates, the method could help to eliminate molecules with too many
potential off-target interactions, or with potential off-target expected to lead to severe
side-effects. On the contrary, the drug candidates whose chemical substructures are
not found in canonical components that do not contain its targeted protein domain
are expected to be of greater interest.
From technical viewpoints, there are several limitations on the proposed SCCA
method. One main difficulty of using SCCA is to choose appropriate sparsity param-
eters and appropriate number of components. High sparsity promoting parameters
would lead to an over-sparse model in all the cases, which might be misleading in
the interpretation if the degree of sparsity was not tuned carefully. According to a
cross-validation, we used top 50 components, but other components may contain bio-
logically meaningful information. The definition of an appropriate objective function
to be maximized or minimized in the cross-validation is an important issue. There
remains much room to develop a more appropriate way to choose the parameters.
Another pitfall of SCCA is that it might not work well when sparsity is not a relevant
characteristic arising from the data. For example, it cannot deal with hierarchically
correlated features in the descriptors of drugs or proteins. An extension of the method
would be to additionally use other constraints which can deal with such a hierarchical
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effect such as the ones presented in [61].
Chapter 4
Phenotypic response to molecular
perturbations
Re´sume´
Caracte´riser la re´ponse phe´notypique a` un stimulus est primordial pour la compre´hension
du comportement d’organismes pluri-cellulaires. Parmis les applications majeures,
on peut citer la mise au point de the´rapies mole´culaires efficaces. Cependant, les
phe´notypes sont bien plus complexes que les interactions mole´culaires, comme celles
conside´re´es dans le chapitre 3. En effet, il existe de multiples possibilite´s pour de´finir
un phe´notype qui implique souvent un grand nombre de cellules. Par ailleurs, la
re´ponse a` un stimulus peut varier de manie`re importante d’un individu a` l’autre. Ce
chapitre est donc de´die´ a` l’e´tude de phe´notypes a` l’e´chelle d’organismes et a` l’e´chelle
de populations de cellules.
Dans une premie`re partie, les effets secondaires de me´dicaments sont conside´re´s
comme des phe´notypes macroscopiques cause´s par les interactions avec un ensem-
ble de prote´ines. Les liens entre la structure chimique et les effets secondaires sont
analyse´s avec une me´thode d’analyse canonique des corre´lations parcimonieuse. Cette
approche permet d’analyser conjointement les relations entre structure chimique et
effets secondaires. Des exemples de modulations d’effets secondaires par la struc-
ture chimique et des relations avec les profils de cibles prote´iques sont donne´s pour
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illustrer les re´sultats produits par cette me´thode. La performance pre´dictive de ces
associations entre structure chimique et effets secondaires sont compare´es a` celles de
me´thodes a` l’e´tat de l’art.
Dans une seconde partie, la question de la comparaison de l’effet de siRNA sur
des phe´notypes de populations de cellules est explore´e. Cette e´tude se base sur
un jeu de donne´es provenant d’une expe´rience de microscopie fluorescente a` haut
de´bit dans le contexte de l’e´tude de la maladie du sarcome d’Ewing. Des indices
provenant de ces donne´es sont propose´s pour motiver le besoin de prendre en compte
la variabilite´ intra-population de la re´ponse cellulaire et la structure de corre´lation
entre les descripteurs utilise´s pour de´crire chaque cellule individuellement. Un mode`le
probabiliste est propose´ afin de prendre en compte ces conside´rations. Des expe´riences
nume´riques montrent que le mode`le propose´ posse`de de meilleures proprie´te´s que celles
d’approches plus na¨ıves pour de´crire la re´ponse a` un siRNA a` l’e´chelle de populations
de cellules.
Abstract
Characterization of the phenotypic effect in response to a stimulus is a key problem in
the understanding of multi-cellular organisms behaviour. This has great implications,
for example in the development of efficient molecular therapies. However phenotypes
are much more complex to describe and study than the molecular mechanisms consid-
ered in chapter 3. Indeed, there are multiple ways to define phenotypes. They usually
involve more than a single cell and there might exist a great variability in phenotypic
responses to stimuli between different individuals. This chapter is dedicated to the
study of phenotypes at the organism level and at the cell population level.
In a first part, drug side effects are considered as macroscopic phenotypes induced
by drugs through interaction with a set of proteins. The relationship between chemical
structure and side effects is investigated using a sparse canonical correlation analysis
method. This approach allows to jointly analyse relations between chemical structure
and side effect profiles for drugs at a large scale. Examples of side effect modulation
through chemical structure variations and relation with protein target profiles are
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provided to illustrate the results provided by the method. Predictive performances
of the extracted associations between structures side-effects are compared to these of
state-of-the-art methods.
In a second part, the question of phenotypic comparison of siRNA effect on cell
populations is investigated. This study is based on data arising from a high through-
put fluorescent microscopy experiment in the context of studying Ewing sarcoma
disease. Evidences arising from data are presented to support the need for taking
into account both variability of the cell response within a population and the cor-
relation structure of individual cell descriptors. A probabilistic model that takes
these questions into consideration is proposed. Numerical experiments demonstrate
that the model has better properties than those of more naive approaches to study
phenotypic response to siRNA at the level of cell populations.
4.1 Introduction
This chapter is dedicated to the study of biological response to a stimulus in terms
of phenotype. By stimulus, it is meant the exposition to perturbing compounds
(marketed drug and siRNA in this chapter). A phenotype results from the effect of
these stimuli on a living system (animal or population of cells). Therefore, the scale of
interest here is at a higher hierarchical level compared to those considered in chapter
3. By nature, phenotypes are more complex to study, some reasons being that
• Phenotypes are result from a whole system of molecules interacting together.
• There is no universal definition of a phenotype and the boundary between two
phenotypes might be fuzzy.
• Phenotypes are variable in the sense that two similar organisms exposed to the
same stimulus might respond in different ways.
The consequences of these remarks are, first that it is necessary to consider a
large number of interacting physical objects (molecules, proteins, cells . . .) in order
to understand how phenotypic effects emerge when a living organism is confronted
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to a stimulus. Second, a phenotype definition should take into account response
variability. The results presented in this chapter illustrate these ideas based on real
world data.
As we mentioned, the concept of phenotype is broad. In this chapter, we consider
two different scales. At the macroscopic level, a phenotype can be understood as a
characteristic of a multi-cellular organism. The example treated in the first section
of this chapter is related to marketed drug side-effects. These are compounds which
have been available on the drug market (which may not be available any more) and
for which side effect data have been collected. A side-effect of a drug can be thought
of as a phenotype. Side-effects are due to interactions of a drug with off targets, i.e.
proteins that do not constitute the main therapeutic target of the drug. They are
observable at the macroscopic scale of a human being.
At the level of a cell, cell cycle phases can be understood as phenotypes. Those
are particularly interesting in cancer therapies, the objective being to disrupt cell
division processes which went out of control. When considering population of cells,
even though cells have been exposed to the same stimulus, there is variability in
cell responses. This variability is also part of the phenotypic response at the cell
population level. These phenomena make it difficult to characterize and compare
stimuli effects at the level of cell populations.
4.1.1 Content of the chapter
The first section of this chapter is dedicated to the analysis of correlations between
drug chemical sub structures and their side-effects. A penalised matrix decompo-
sition is used to investigate these correlations which are further used in side-effect
prediction contexts. This is compared to state-of-the-art supervised methods. The
results presented in this part are based on the work presented in [94] together with
results from [136].
In a second section, we consider cell population phenotypes. Numerical exper-
iments are based on control data from siRNA knock down high content screening
experiments in the context of Ewing sarcoma. This study is part of a wider research
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project that aims at identifying genes that play a role in Ewing sarcoma. A probabilis-
tic model is proposed to tackle the issue of comparing images of cell populations with
heterogeneous individual phenotypes. This section is based on the results presented
in [95].
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4.2 Sparse canonical correlation based drug side-
effect analysis
This section is mostly based on the results presented in [94]. The focus is on the
relation between adverse drug reactions and drug chemical structure. A matrix de-
composition method is applied to extract associations between chemical substructures
and drug side-effects which are further used in a supervised prediction context. [136]
extended this work by integrating both chemical and protein target profiles in a
side-effect prediction context. These results are qualitatively described in the last
paragraph.
4.2.1 Background
Drug side-effects
Drug side-effects, or adverse drug reactions, have become a major public health con-
cern. It is one of the main causes of failure in the process of drug development, and of
drug withdrawal once they have reached the market. As an illustration of the extent
of this problem, serious drug side-effects are estimated to be the fourth largest cause
of death in the United States, resulting in 100,000 deaths per year [42]. In order to
reduce these risks, many efforts have been devoted to relate severe side-effects to some
specific genetic biomarkers. This so-called pharmacogenomics strategy is a rapidly
developing field, especially in oncology [56]. The aim is to prescribe a drug to patients
who will benefit from it, while avoiding life threatening side-effects [84].
From a system viewpoint, drugs can be regarded as molecules that induce per-
turbations to biological systems consisting of various molecular interactions such as
protein-protein interactions, metabolic pathways and signal transduction pathways,
leading to the observed side-effects [119]. The most common perturbation mechanism
is to bind to a protein, thereby modifying its function. These mechanisms have been
investigated in chapter 3. Actually, the body’s response to a drug reflects not only the
expected favorable effects due to the interaction with its target, but also integrates the
overall impact of off-target interactions. Indeed, even if a drug has a strong affinity for
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its target, it also often binds to other protein pockets with varying affinities, leading
to potential side-effects. This concept has been illustrated by comparing pathways
affected by toxic compounds and those affected by non-toxic compounds, establishing
links between drug side-effects and biological pathways [103].
In silico prediction
Although preclinical in vitro safety profiling can be used to predict side-effects by test-
ing compounds with biochemical and cellular assays, experimental detection of drug
side-effects remains very challenging in terms of cost and efficiency [127]. There-
fore, in silico prediction of potential side-effects early in the drug discovery process,
before reaching the clinical stages, is of great interest to improve this long and expen-
sive process and to provide new efficient and safe therapies for patients. This task
intrisically requires to consider the whole system of proteins in order to determine
macroscopic consequences of disturbing biological processes at the molecular scale.
Expert systems based on the knowledge of human experts have been developed to
predict the toxicity of molecules based on the presence or absence of toxic moieties
in their chemical structure. For example, they predict potential toxicity such as mu-
tagenicity, but they do not provide prediction for numerous potential side-effects in
human [12]. Recently, several computational methods for predicting side-effects have
been proposed, which can be categorized into pathway-based approaches and chemical
structure-based approaches.
The principle of pathway-based approaches is to relate drug side-effects to per-
turbed biological pathways or sub-pathways because these pathways involve proteins
targeted by the drug. In a pioneer work to illustrate this concept, it has been shown
that drugs with similar side-effects tend to share similar profiles of protein targets
[19]. The authors further exploited this characteristic to predict missing drug tar-
gets for known drugs using side-effect similarity. [38] proposed a method for relating
side-effects to cooperative pathways defined as sub-pathways sharing correlated mod-
ifications of gene expression profiles in presence of the drug of interest. However,
this method requires gene expression data observed under chemical perturbation of
the drug. [131] developed a method to identify off-targets for a drug by docking this
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drug into proteins binding pocket similar to that of its primary target. The drug-
protein interactions with the best docking scores are incorporated to known biologi-
cal pathways, which allows to identify potential off-target binding networks for this
drug. However, the performance of this method depends heavily on the availability
of protein 3D structures and known biological pathways, which limits its large-scale
applicability.
The principle of chemical structure-based approaches is to relate drug side-effects
to their chemical structures. [102] developed a method that identifies chemical sub-
structures associated to side-effects. However, this method does not provide an in-
tegrated framework to predict side-effects for any drug molecule. [135] proposed a
method to predict pharmacological and side-effect information using chemical struc-
tures, which is then used to infer drug-target interactions. However, the method
cannot be applied to predict high-dimensional side-effect profiles.
Content of this section
This section describes a canonical correlation based approach (CCA) to predict poten-
tial side-effect profiles of drug candidate molecules based on their chemical structures,
which is applicable on large molecular databanks. In addition, the proposed method
is able to extract correlated sets of chemical substructures (or chemical fragments)
and side-effects. Sparsity inducing constraints allows to ease the interpretation of the
extracted correlated sets. The corresponding method is described in chapter 2 and is
referred to as sparse canonical correlation analysis (SCCA).
Numerical experiments show the usefulness of the proposed method on the pre-
diction of 1385 side-effects in the SIDER database from the chemical structures of
888 approved drugs. These predictions are performed with simultaneous extraction of
correlated ensembles formed by a set of chemical substructures shared by drugs that
are likely to have a set of side-effects. The relevance of the information extracted by
the method is demonstrated on specific examples. We also conduct a comprehensive
side-effect prediction for many uncharacterized drug molecules stored in DrugBank
database, and were able to confirm interesting predictions using independent source
of information.
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The natural step forward is the integration of both chemical structure and protein
interaction profiles to predict uncharacterized drug side-effects. This has been done
in a further study [136], which results are qualitatively described at the end of the
section.
4.2.2 Materials
Side-effect keywords were obtained from the SIDER database which contains informa-
tion about marketed medicines and their recorded adverse drug reactions [82]. This
led to build a dataset containing 888 drugs and 1385 side-effect keywords. Each drug
was represented by a 1385 dimensional binary profile y whose elements encode for the
presence or absence of each of the side-effect keywords by 1 or 0, respectively. There
are 61,102 associations between drugs and side-effect terms in the dataset, and each
drug has 68.8 side-effects on average. This dataset is used to evaluate the performance
of the proposed methods in this study.
To encode the drug chemical structure, we used a fingerprint corresponding to
the 881 chemical substructures defined in the PubChem database [22]. Each drug
was represented by an 881 dimensional binary profile x whose elements encode for
the presence or absence of each PubChem substructure by 1 or 0, respectively. A
description of the 881 chemical substructures can be found at the PubChem website
[22]. There are 107,292 associations between drugs and chemical substructures in the
dataset, and each drug has 120.8 substructures on average.
The other drug information (e.g., ATC code, drug category, protein target) was
obtained from DrugBank [128]. This information is used to ease biological interpre-
tation in the side-effect prediction for uncharacterized drugs.
4.2.3 Methods
We propose five possible methods to predict drug side-effect profiles from the chemical
structures. We have a training set of n drugs with p substructure features and q side-
effect features. Each drug is represented by a chemical substructure feature vector
x = (x1, · · · , xp)T , and by a side-effect feature vector y = (y1, · · · , yq)T . We consider
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X the n× p matrix defined as X = [x1, · · · ,xn]T , and Y the n× q matrix defined as
Y = [y1, · · · ,yn]T , where the columns of X and Y are assumed to be centered and
scaled.
Sparse canonical correlation analysis (SCCA) and side-effect prediction
Consider two linear combinations for chemical substructures and side-effects as ui =
αTxi and vi = β
Tyi (i = 1, 2, · · · , n), where α = (α1, · · · , αp)T and β = (β1, · · · , βq)T
are weight vectors. As presented in chapter 2, the SCCA method we consider here
consists in finding the weight vectors α and β which solve the following L1 constrained
optimization problem:
max{αTXTY β} subject to
||α||22 ≤ 1, ||β||22 ≤ 1, ||α||1 ≤ c1
√
p, ||β||1 ≤ c2√q, (4.1)
where || · ||1 is L1 norm (the sum of absolute values of vector entries), c1 and c2 are
parameters to control the sparsity and restricted to range 0 ≤ c1 ≤ 1 and 0 ≤ c2 ≤ 1.
For simplicity, we use the same value for c1 and c2 in this study. The sparse version
of CCA is referred to as sparse canonical correlation analysis (SCCA). Setting c1 =
c2 = 1 defines the original CCA (OCCA) without sparsity constraint and amounts to
compute an SVD (see chapter 2). Problem (4.1) can be regarded as the problem of
penalized matrix decomposition of the matrix Z = XTY . As mentioned in chapter
2, we can use the penalized matrix decomposition (PMD) proposed by [129]. After
m iterations of the algorithm, we obtain m pairs of weight vectors α1, · · · ,αm and
β1, · · · ,βm which are referred to as components with associated weights ρ1, · · · , ρm.
Components of lower k are called “lower order components”, while components of
higher k are called “higher order components”.
If the extracted sets of chemical substructures and side-effects are biologically
meaningful, potential side-effects for a new drug candidate molecule should be pre-
dicted comparing the extracted chemical substructures to its chemical structure.
Given the chemical structure profile x of a new drug candidate molecule, its po-
tential side-effect profile y can be predicted based on the extracted sets of chemical
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substructures and side-effects encoded in {αk}mk=1 and {βk}mk=1. We use the prediction
score described in chapter 2.
yˆ =
m∑
k=1
βkρkα
T
k x, (4.2)
Note that yˆ is the q-dimensional vector whose j-th element represents a prediction
score for the j-th side-effect. If the j-th element in yˆ has a high score, the new
molecule x is predicted to lead to the j-th side-effect (j = 1, 2, · · · , q).
Support vector machine (SVM)
The side-effect prediction problem can be viewed as a supervised binary classification
problem consisting in predicting whether a given drug x has a side-effect or not. This
should be repeated for all q side-effects. The support vector machine (SVM) is a
well-known binary classifier, and it has become a popular classification method in
bioinformatics [39] and chemoinformatics [79] because of its high-performance pre-
diction ability [105]. We test several kernel functions such as linear kernel, Gaussian
RBF kernel with various width parameters, and polynomial kernel with various degree
parameters. Note that this strategy needs to construct q individual SVM classifiers
for q side-effects, so it will require considerable computational burden, because q is
quite huge in practical applications (q ∼ 1000 in this study). Choice of kernel and its
parameter were made using cross validation.
Nearest neighbor (NN)
The most straightforward approach is to apply the nearest neighbor (NN), which
predicts a given drug x to have the same side-effects as those of the drug (in a
training set) whose chemical substructure profile is the most similar. For each query
drug, we look for k nearest neighbors, and if k′ of k have a side-effect, we assign the
prediction score of k′/k to the query drug. We repeat this procedure for q side-effects.
The number of neighbours k was obtained by cross validation.
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Figure 4.1: ROC curves comparing the performances of nearest neighbor (NN), sup-
port vector machine (SVM), ordinary canonical correlation analysis (OCCA) and
sparse canonical correlation analysis (SCCA) for side-effect prediction.
Random assignment (Random)
To evaluate how difficult the problem considered is, we apply a random assignment
procedure, that is, we use the 0/1 ratio to assign a binary label to each test drug
randomly. For example, if the ratio in given training data is 90%, we can assign zero
for 90% of examples in test; otherwise 1. This method is used as a baseline method
in this study.
4.2.4 Results
Performance evaluation
We applied nearest neighbor (NN), support vector machine (SVM), ordinary canon-
ical correlation analysis (OCCA), and sparse canonical correlation analysis (SCCA)
to predict drug side-effect profiles. We also applied random assignment procedure
(Random) as a baseline method. First we tested the five methods: Random, NN,
SVM, OCCA and SCCA for their abilities to predict known side-effects profiles by
the following 5-fold cross-validation. Drugs in the side-effect data were split into 5
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subsets of roughly equal size, each subset was then taken in turn as a test set, and
we performed the training on the remaining 4 sets. For accurate comparison, we kept
the same experimental conditions, where the same training drugs and test drugs are
used across the different methods in each cross-validation fold. We evaluated the per-
formance of each method by the ROC (receiver operating characteristic) curve [47],
which is a graphical plot of the sensitivity, or true positive rate, against false positive
rate (1-specificity or 1-true negative rate). The ROC curve can be represented by
plotting the fraction of true positives out of the positives (true positive rate) vs. the
fraction of false positives out of the negatives (false positive rate), where true posi-
tives are correctly predicted side-effects and false positives are incorrectly predicted
side-effects based on the prediction score for various threshold values above which the
output is predicted as positive and negative otherwise.
Figure 4.1 shows the ROC curves for the five different methods based on the cross-
validation experiment, where the prediction scores for all side-effects were merged
and a global ROC curve was drawn for each method. Parameters in each method
were chosen by using the AUC (area under the ROC curve) score as an objective
function. The best result for NN was obtained by the number of neighbors k = 50.
The best result for SVM was obtained by Gaussian RBF kernel with width parameter
σ = 0.2 and regularization parameter C = 1. The best result for OCCA was obtained
by m = 20. The best result for SCCA was obtained by the following parameters:
c1 = c2 = 0.05 and m = 20. The resulting AUC scores for Random, NN, SVM,
OCCA and SCCA are 0.6088, 0.8917, 0.8930, 0.8651 and 0.8932, respectively. From
this figure 4.1 we see that the proposed SCCA method outperforms OCCA and its
performance is at a competitive level with NN and SVM.
We are also interested in biological interpretability of the outputs of the pro-
posed method to understand the relationship between chemical substructures and
side-effects. We focused on OCCA and SCCA, because they are the only methods
which can correlate two heterogeneous high-dimentional data sets. We examined the
weight vectors for drug chemical substructures and drug side-effects in OCCA and
SCCA. Figure 4.2 shows the index-plot of weight vectors in OCCA, and figure 4.3
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Figure 4.2: Index-plot of weight vectors for drug substructures (upper) and side-
effects (lower) extracted by ordinary canonical correlation analysis (OCCA).
shows the index-plot of weight vectors in SCCA, where the first eight canonical com-
ponents are shown. Almost all elements in the weight vectors extracted using OCCA
are non-zero and highly variable, while most of the elements in the weight vectors ex-
tracted using SCCA are zero in each component. This underlines the fact that SCCA
can select a small number of features as informative drug substructures and side-
effects. This result suggests that the proposed SCCA method provides more selective
and informative correlation between drug substructures and side-effects without loos-
ing performance. In addition, it should be pointed out that the other methods NN
and SVM do not provide any clue for biological interpretation.
Finally, we investigated the computational cost for each method. Figure 4.4 shows
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Figure 4.3: Index-plot of weight vectors for drug substructures (upper) and side-effects
(lower) extracted by sparse canonical correlation analysis (SCCA).
the total execution times of the cross-validation experiment between the four different
methods. NN is the fastest, followed by OCCA, SCCA, and SVM. As expected, SVM
is much slower than the other methods, because it requires individual classifiers for
all side-effect keywords (∼ 1000 SVM classifiers are required).
Extracted sets of drug substructures and side-effects
From biological viewpoints, we examined the extracted sets of drug substructures and
drug side-effects in each canonical component extracted using SCCA. Note that the
other methods (NN, SVM, and OCCA) do not enable us to interpret the biological
features. Each component consists of only a small number of substructures and a
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Figure 4.4: Total execution time of the cross-validation experiment for the four meth-
ods (log10 scale).
small number of side-effects that are correlated with each other according to SCCA.
For each component, two lists of drugs are provided: one containing drugs with a
high score for the associated substructures, and one containing drugs with a high
score for the associated side-effects. We examined the results when we used the best
parameters which provided the highest AUC for all side-effect terms. The content of
a few canonical components are discussed to illustrate the ability of the method to
extract meaningful biological information.
A canonical correlation coefficient is computed to evaluate the importance of
each component. This value corresponds to the value of the objective of (4.1) for
each component. The components with high canonical correlation tend to con-
tain rare substructures present only in very few drugs, which are associated to rare
side-effects mainly observed for these drugs. These components contain quite spe-
cific substructure/side-effect canonical correlations whose interpretation is straight-
forward. For example, component 6 associates the presence of a boron atom, only
found in the bortezomid molecule in the SIDER database, to a short list of neuro-
logical side-effects observed only for this drug. Similarly, component 20 essentially
clusters a substructure defined by a carbon atom bearing both a bromide atom and a
nitrogen atom. This substructure is found only in the bromocriptine molecule of the
SIDER database, with two side-effects observed only for this drug (namely, pregnancy
induced hypertension and toxemia of pregnancy).
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Table 4.1: Nitrogen-containing rings of size 5: (A) Porphyrin group, (B) Proline
residue, (C) Histidine residue, (D) Tryptophane residue.
A B C D
In the general case of components containing more frequent substructures, drugs
that contain these substructures tend to present side-effects associated to this compo-
nent, but this correspondence is not strict. Reciprocally, most drugs that have high
scores for the side-effects contain the chemical substructures of this component, but
not all. Analysis of component 18 can illustrate these points.
This component contains two substructures, the major one being the presence of
“four or more saturated or aromatic nitrogen-containing rings of size 5”, associated
to four side-effects. This substructure is present in five drugs of the SIDER database:
verteporfin, porfimer, goserelin, buserelin, and leuprolide. Verteporfin and porfimer
contain a porphyrin group displaying four nitrogen-containing rings of size 5, as shown
in figure 4.1 (A). Goserelin, buserelin, and leuprolide are synthetic 9-residue peptide
analogues of the gonadotropin releasing hormone. Their sequences contain amino-
acids whose chemical structures present nitrogen-containing rings of size 5, found in
side chains of proline, histidine or tryptophane residues, as shown in figure 4.1 (B),
(C) and (D). Overall, four or more nitrogen-containing rings of size 5 are indeed
present in their structures.
Note however that these rings are different from those of the porphyrin group.
Although goserelin, buserelin and leuprolide on the one hand, and verteporfin and
porfimer on the other hand, belong to totally unrelated families of molecules, they
share common substructures, at least according to their definition in the present
study. All drugs from these two families, but verteporfirin, have high scores for
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Figure 4.5: Two dimensional graph structure of risperidone.
side-effects of this component. This result illustrates the fact that side-effects of a
drug is usually associated to the presence of given substructures, although it may be
modulated by the overall molecular structure, as in the case of verteporfirin. This
property is also well known in the context of drug structure-activity relationship,
which usually depends on given molecular scaffolds, but which is modulated by the
presence of additional chemical groups.
Reciprocally, all drugs that have high scores for side-effects of component 18 con-
tain the chemical substructures of this component, but risperidone, as shown in figure
4.5. Its structure is very different from those of porphyrins or gonadotropin analogues.
It is an antagonist of the dopamine and of the serotonine receptors. It belongs to
the class of antipsychotic agents (see DrugBank), and its high score for side-effects of
component 18 cannot be explained in a straightforward manner.
However, in some cases, we were able to relate such unexpected results to the
targets of these drugs, as illustrated by component 13. This component contains
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substructures that are essentially present in proton pump inhibitors used as anti-
ulcer agents like omeprazole. It is also present in a small number of drugs from
other families like pramipexole (an antiparkinson agent) or riluzone (a neuroprotective
agent). As expected, these anti-ulcer agents are found in the high scoring drugs for
side-effects in component 13, together with pramipexole and riluzone, although with
lower scores. As for component 18, other drugs that do not contain the high scoring
substructures of component 13 are however found among high scoring drugs for side-
effects in this component. This is the case of ropinirole. Interestingly, ropinirole is an
antiparkinson agent that targets the same protein as pramipexole, namely dopamine
receptor.
This result suggests that drugs sharing some protein targets may also share some
side-effects. It is also consistent with the idea that the global biological effect of
a molecule (both beneficial effects and adverse side-effects) is related to its overall
profile of protein targets. Taken together, our results provide examples for which
the side-effects of a drug are modulated both by its substructures and by its targets.
Note that these two factors are connected since similar molecules tend to share similar
protein targets, but this property was not exploited in the present study.
Comprehensive side-effect prediction for uncharacterized drugs
We then evaluated the interest of the proposed method for prediction of side-effects for
uncharacterized drugs. We predicted potential side-effects for drugs in DrugBank for
which side-effect information was not available in the SIDER database. We focused
on 2883 drugs which are labeled as “small molecules” in DrugBank. We first make
general comments on the results and then present more details for a few well-known
specific examples.
Very frequent side-effects, such as “headache” or “nausea” are found in SIDER,
and they occur with many drugs. These side-effects are not specific, and they do
not appear for a well defined drug category. They are the most frequently predicted
side-effects, but they hardly appear with the highest prediction scores for a given
drug, which is consistent with the fact that they are common reactions. However,
we also find more specific side-effects which are related to special types of drugs.
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For example, steroids may lead to “striae”, or “linear atrophy”, which results in
local dermal structure atrophy and skin depigmentation [80]. Indeed, this keyword
is mainly found for steroid molecules in SIDER. The top 30 drugs predicted to have
this side-effect are also steroids, which is consistent with literature and training data.
Moreover, “global amnesia”, a very specific keyword in SIDER, is one of the most
striking syndromes in clinical neurology whose underlying causes are not well known
[101]. 14 drugs catch a high prediction score for this keyword. Among them, one is
anticholesteremic, three are antipsychotics, and the others are experimental molecules
whose categories are not known. Therefore, three out of four drugs with known
indications are related to cognitive functions, which is consistent with the predicted
side-effect nature. Although the accuracy of all the predictions was not discussed
here, the results are consistent with the available biological and medical information.
We also checked famous examples of withdrawn drugs. Rimonabant (DB06155 in
DrugBank) is an anti-obesity agent. It was rejected for approval in the United States,
but it was accepted in Europe in 2006. In october 2008, the European Medicines
Agency recommended suspension of its marketing authorization because of serious
psychic side-effects, mainly severe depression. Indeed, this drug is active in the cen-
tral nervous system, which may trigger very broad and complex psychic mechanisms.
Consistent with this, in our prediction profile, the “borderline personality disorder”
and “posttraumatic stress disorder” keywords are found in the ten top ranking key-
words for this drug. In other words, our method would have foreseen potential psy-
choactivity for rimonabant. Furthermore, the method provides a potential rationale
for appearance of these psychotic effets. Rimonabant contains the substructure shown
in figure 4.6. This substructure is also found in the alprazolam molecule used in the
treatment of psychic disorders (a molecule in SIDER). Interestingly, among the 165
molecules of PubChem that also share this substructure and for which pharmacolog-
ical annotation is available, 40 are classified as ”anti-anxiety agents”. A reasonable
hypothesis to explain rimonabant’s severe side-effects may be the presence of this
substructure, together with the nature of its protein target (namely, the cannabinoid
receptor).
Terfenadine (DB00342 in DrugBank) is an anti-allergic agent which was withdrawn
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Figure 4.6: The substructure of Rimonabant selected to be a clue of psychoacticity.
by the U.S. Food and Drug Administration in 1997 because of toxic effects on heart
rhythm. The “Aortic stenosis” and “aortic valve incompetence” keywords rank 9-th
and 11-th among the predicted side-effects for this drug. These related side-effects
are known to often lead to arrhythmias [98], as observed for this drug. In this case
again, our method would have foreseen potential severe cardiac side-effects.
4.2.5 Discussion and conclusion
In this section we investigate the question of predicting potential side-effect profiles
of drug candidate molecules based on their chemical structures using sparse canonical
correlation analysis (SCCA). The method is computationally efficient and is appli-
cable on large datasets. From a system perspective, the originality of the proposed
method lies in the integration of chemical space and pharmacological space in a uni-
fied framework, in the extraction of correlated sets of chemical substructures and
side-effects, and in the prediction of a large number of potential side-effects in a row.
Numerical experiments suggest that the method is competitive with state-of-the-
art approaches in the task of predicting drug side-effects based on chemical structure.
After training the method using publicly available data, we could predict side-effect
for out of sample molecules which we could confirm using independent information
sources.
One main difficulty of using SCCA is to choose appropriate sparsity parameters
and appropriate number of components. High sparsity promoting parameters would
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lead to an over-sparse model in all the cases, which might be misleading in the inter-
pretation if the degree of sparsity was not tuned carefully. The optimal parameters
value depends highly on the definition of the objective function to be investigated in
the cross validation. We evaluated global prediction accuracy, involving all possible
drug-side-effect associations. The definition of an appropriate objective function in
the cross-validation is an important issue. There remains much room to develop a
more appropriate way to choose the parameters, depending on the goal of the analysis.
The proposed method can be applied at various stages of the drug development
process. At early stages, among several active drug candidates, the method could
help to choose the molecules that should further continue the process and those that
should be dropped. It could also help to find new indications for known drugs,
a process named drug repurposing. Indeed, side-effects of drugs used in a given
pathology can be viewed as a beneficial effect in another pathology. Sildenafil is
a famous example of such drug repositioning. The method could help to identify
chemical substructures of known drugs that might participate in the appearance of a
given side-effect. These substructures could be used as building blocks in fragment-
based drug discovery approaches [44] for pathologies in which this side-effect could
be positively exploited.
Experimental results suggest that the SCCA approach is competitive with state-of-
the-art methods in term of prediction accuracy. It associates chemical substructures
and protein domains in components. From a biological point of view, we provide
examples that illustrate the modulation of drug side-effects by chemical structure.
These examples were provided by the analysis of extracted components. The under-
lying mechanical mechanism is the protein ligand interaction that we investigated in
chapter 3. Drugs perturb biological process by interacting with the corresponding
proteins. Therefore a logical continuation of this work is to integrate both chemi-
cal and protein target information in order to predict side-effects. The next section
describes an extension of this work based on this idea.
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4.2.6 Integrating different sources of information
An extension of this work was proposed in [136] which we briefly outline in this
paragraph. In this section, we considered predicting drug side-effects from chemical
structure. As mentioned in the introduction and in chapter 3, drug side-effects are the
result of the interactions between the drug and all its targets. This point was further
illustrated by giving examples of chemical substructure and side-effect association
which were coherent in terms of protein target interaction profiles. These examples
were extracted using SCCA method without incorporating this target profile infor-
mation in the analysis. The next step is to include protein target information for
side-effect prediction. Moreover, both chemical information and protein target infor-
mation can be combined to achieve potentially greater accuracy on this prediction
task.
[136] proposes to use kernel regression to integrate chemical and protein target
information to predict side-effects. The protein and ligand information used is similar
to those used in chapter 3, and the chemical and side-effect information are the same
as in the present section (see section 4.2.2). Kernels offer a flexible framework to
combine different sources of information to make predictions. Using properties such
as additivity, it is possible to build kernel reflecting both chemical similarity and
target protein profile similarity for drugs. Kernel regression consists in combining
the square loss with a class of functions defined by a positive definite kernel in a
supervised learning framework. Solving the kernel regression problem can be done in
closed form and requires a matrix inversion.
Based on an extension of the dataset presented in this section (including protein
target information from DrugBank database [128] and Matador database [49]), the
work of [136] compares the CCA based methods and kernel regression based methods
when considering chemical information or protein target information separately or
considering the integration of both sources of information. The results presented in
[136] suggest that using both sources of information significantly improve the per-
formances in predicting side-effects for drugs when using kernel regression methods.
Although the problem tackled in the present section is very similar to that of this
extension, it is not possible to compare them quantitatively. Indeed, [136] is based on
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a slightly different dataset and filters very frequent side-effects. Moreover, the perfor-
mance metrics used are different (precision recall curve instead of Receiver Operating
Characteristic).
Finally, the methods proposed in [136] only consider performance on side-effect
prediction tasks and do not provide any interpretable biological feature. Therefore,
they do not provide any clue to associate chemical fragments with specific side-effect
as we presented in the previous section. However, the study presented in [136] demon-
strates on the drug side-effect prediction task that the integration of different sources
of informations improves the prediction accuracy. This is a natural extension of
the study presented in this section and a contribution to the development of system
based approaches in the context of phenotypic characterization of un-marketed small
molecules.
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4.3 Cell population phenotyping
This section is dedicated to the study of the phenotypic effect of siRNA gene knock
down experiments based on high content screening data. A siRNA is a small RNA
molecule which is able to bind a specific messenger RNA in order to prevent the
translation of the underlying gene. This process results in the silencing of further
molecular mechanisms and may finally cause a phenotypic change at a higher level
in the hierarchy of biological scales. The biological scale considered here is that of
populations of cells. At such a scale, a group of cells can be viewed as a system
which organization holds information about the behaviour of the group as a whole.
The introduction describes the technology and motivates the necessity to take into
account variability within a population of cells and descriptors dependence structure.
These specific considerations arise from the fact that we consider groups of cell as
complex entities. Indeed, they do not apply when considering cells as separate entities.
Preliminary numerical analyses reinforce these remarks based on experimental data.
A probabilistic model is described and its properties are investigated in terms of
phenotypes at the level of cell populations. The results presented are based on the
work published in [95].
4.3.1 Introduction
High content screening data processing
Fluorescent markers allow to label virtually any cellular structure in living cells [43].
Recent advances in sample preparation and microscopy automation allow cell popula-
tion imaging on a large scale [96]. Both technologies lead to the development of High
Content Screening (HCS) platforms which allow screening living cells under a wide
range of experimental conditions. Classically, the aim is to identify a therapeutic
target, or a drug candidate. One screen consists in taking several pictures of a large
number of cell populations, for example, transfected with RNAi tools or exposed to
small molecules. Each experiment is performed in a well in which several pictures are
taken, called fields. It gives access to a whole panel of cellular responses to a specific
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manipulation. The outcome is a series of cell population images which holds much
more information than the single averaged value of the cellular response, classically
recorded in HTS screens. The available information accounts for cell variability ac-
cording to various features, which is precious to characterize a population of cells.
However, the heterogeneity of cellular responses makes it difficult to compare and
interpret experiments. In the framework we consider in this work, processing the
outputs of such experiments requires three steps as illustrated in Figure 4.7.
• Step 1, segmentation: This step consists in identifying cells in images and
extract features that characterize the shape and texture for each individual cell.
• Step 2, cellular phenotyping: This step usually involves machine learning
algorithms that classify cells according to different predefined cellular pheno-
types based on cellular features and on a training set of annotated cells for
which this phenotype is known.
• Step 3, population phenotyping: This step aims at defining phenotypes (or
classes) at a population level, using population descriptors derived from cellular
phenotypes, in order to describe and compare different experiments.
Segmentation and cellular phenotyping steps have been well studied (steps 1 and 2).
There has been a huge amount of work to apply image processing tools to cell seg-
mentation and cell features extraction from cell population images. Typical cellular
features used in this context are nucleus and cytoplasm size, texture and shape. The
cellular phenotyping step aims at converting, for each single cell, the numerical val-
ues corresponding to its cellular features into predefined biological phenotypes that
are relevant at the cellular scale and characterize the cell status. Typical examples
are cell morphology classes, such as shape and appearance or cell cycle state (G1, S,
G2 or M phases). Coupling the image segmentation step with supervised machine
learning algorithms, many authors proposed methods to classify cells according to
various predefined cellular phenotypes using HCS data and a training set of anno-
tated cells [24, 125, 65]. These applications developed in the last decade demonstrate
empirically the effectiveness of machine learning algorithms in this setting. Example
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Figure 4.7: HCS data acquisition and processing. After experimental acquisition, we
have four images, or fields, per well. Step 1 consists of isolating each cell in each image
and computing cell features by means of image processing tools. These features are
used to classify cells in each image according to different predefined cell phenotypes
in a second step (for example M, G2 phases or apoptosis). This classification provides
population descriptors that can be used to define population phenotypic classes.
of algorithms used in this context are state-of-the-art classification algorithms such
as support vector machines [112] or boosting [36].
Analysis methods
A common practice in HCS analysis is to inspect univariate cell features averaged
over wells [99, 13, 17]. This is suited for analysis of a single channel (for example
corresponding to a single cellular phenotype such as “apoptosis state”). However,
analysis of multiple cellular phenotypes may require to take into account their joint
distributions. In our setting, cells from images are phenotyped in steps 1 and 2. As
there are many potential cell phenotypes of interest, the multivariate setting must
be considered, which constitutes a characteristic of the proposed method. Moreover,
our model accounts for the field variability in each well, not only averaged values
over wells. This constitutes a step toward cell variability characterization within each
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well, since within a population of cells in a well, one may observe a range of cellular
responses to a given experimental condition. Indeed [113] observe a significant impact
of the cell population context on the cellular phenotypes in siRNA screens. They
found that local cell density, position of a cell in the local cell population or cell size
significantly influence phenotypes such as viral infection or endocytosis.
In an HCS experiment, once, all cells of a population (namely all cells of a well)
have been assigned cellular phenotypes, the aim is to characterize this cell population
(step 3). In other words, we would like to define a population phenotype based on the
cellular phenotypes of all the individual cells it contains, since different cells taken
from the same well can display different cellular phenotypes, even when exposed to
the same experimental conditions. Therefore, cellular phenotypes cannot be used
as population phenotypes in a straightforward manner, and it remains a challenging
issue to fill the gap between phenotypical characterization of a population of cells
and single cell phenotypes. In particular, definition of population phenotypes is an
important issue that one must solve in order to compare cell populations subject
to different treatments. For example [37] carry out the segmentation and cellular
phenotyping steps and propose a distance learning method to compare different cell
populations, and generalize known relations between experiments in a third step.
In a different experimental setting, [89] use trajectories defined by time varying cell
population responses to compare treatments.
Content of this section
In this section, we present a method to describe and compare populations of cells
in HCS experiments by defining population phenotypes. The input of the proposed
method is a table in which each row is a field (an image) and each column is a
population descriptor for these fields. For each well several fields are recorded, and
well assignment information is available for each field. However, the behaviour of
fields within the same well might be different. We refer to this aspect as “within-
population variability”. Moreover, population phenotyping should not only take into
account each single population descriptor individually, but also the joint distribution
of these descriptors. We refer to this as “dependence structure of cell population
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descriptors”. Taking this dependence structure into account improves the description
power of the model. Illustration of these aspects of our HCS dataset and further
biological motivations will be presented in the method section.
Going back to the HCS data analysis framework presented in Figure 4.7, the
proposed method tackles step 3: population phenotyping. A natural approach to
characterize a population of cells is to consider the output of the first two steps as
descriptors for the population of cells. The total number of cells and the proportion
of cells assigned to each predefined cellular phenotype describe the joint behaviour of
all cells in a given population. The problem is now to assign a population phenotype
based on the descriptors of this cell population. For example, in the present study, we
aim at defining population phenotypes based on the following population descriptors
: cell count, and cellular phenotypes which are represented by proportions of cells in
the different stages of the cell cycle. A population phenotype is meant to characterize
the biological state of the cell population in a given experiment. Each population
phenotype (or class) should gather cells which behaviours are similar, and population
of cells showing dissimilar behaviours should be assigned to different classes. The
conceptual difference with the cellular phenotyping step (step 2) is that we do not
have predefined population phenotypes, nor do we have annotated cell populations
according to population phenotypes. Indeed, the question of how to define such
population phenotypes is still open. Therefore, while a supervised framework is suited
for solving step 2, because there exists predefined cellular phenotypes, we propose
an unsupervised method to tackle the population phenotyping step (stpe 3) where
predefined cell population phenotypes are unknown.
We model a cell population using a hierarchical mixture model which is a specific
kind of bayesian network, a widely-used class of probabilistic models [78]. “Within-
population variability” is modelled using a hierarchical structure and “dependence
structure of cell population descriptors” is modelled using multivariate probability
distributions. The output of the method characterizes the density of the input fields
in the population descriptors space and assigns a phenotypic class to each well. A
copula-based parametrization is compared to a gaussian parametrization of the pro-
posed mixture model (details are found in the methods section). To validate our
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hypotheses regarding “within-population variability” and “dependence structure of
cell population descriptors”, we compare performances of the two preceding models
to a baseline gaussian mixture model with diagonal covariance matrix, which would
correspond to ignoring these two aspects of the data.
In summary, the proposed method is a tool for analysing cell population data. It
relies on prior image segmentation and cellular phenotype assignment which corre-
sponds to steps 1 and 2 of this analysis framework. The main purpose of the method
is to extract cell population phenotypes and to assess phenotypic variability at the
level of cell populations. The model allows to take advantage of HCS specific in-
formation: “dependence structure of population descriptors” and “within-population
variability”, which our experiments suggest to consider in our context. This can be
used to tackle the problem of novelty detection (for example, outlier genes in a siRNA
experiment), which is one of the main goals of HCS experiments. We validate a HCS
data analysis method based on control experiments. It accounts for HCS specificities
that were not taken into account by previous methods but have a sound biological
meaning. Biological validation of previously unknown outputs of the method consti-
tutes a future line of work.
4.3.2 Materials and Methods
Experimental acquisition
siRNA screening was performed on shA673-1C Ewing sarcoma derived cell line [121]
by the Biophenics platform at Institute Curie. Two experimental conditions were
considered: cells were either transfected with a negative siRNA controls (Luciferase
GL2 siRNA, Qiagen) or a positive siRNA control (KIF11). Cell numeration and
mitotic figures were determined using DAPI staining, cycle phases distinction were
determined using EdU (for S Phase) and Cyclin B1 (for G2-M transition) immunoflu-
orescence staining. Apoptosis was detected by cleaved caspase 3 immunofluorescence
staining. Images were acquired on IN Cell1000 Analyzer (GE Healthcare Life Sci-
ences) and segmented using IN Cell Investigator software.
80 CHAPTER 4. PHENOTYPIC RESPONSE
Dataset
Our dataset is comprised of 2688 fields belonging to 672 wells for which we have total
cell count and proportions in S, G2, M and Apoptotic phases. Each well is either
related to a GL2 or a KIF11 experiment. In addition , we have well assignment
information for each field (336 wells x 4 fields per well x 2 manipulations = 2688
fields). Note that cellular phenotypes are not exclusive here. This dataset is one
example of output of the two first steps we mentioned in the introduction and the
purpose of this study is to validate our method based on it. The proportion of cells
in the G0/G1 phases is deduced from the total of those in the S, G2, M.
Preliminary data analysis
To motivate the need for accounting for “dependence structure of population descrip-
tors” and “within-population variability”, we present two simple observations arising
from the dataset described in the previous paragraph.
First, we studied the association between cell population descriptors. More pre-
cisely, we searched for potential positive or negative correlation between the cell count
and the other population descriptors. As shown in Table 4.3.2, there is no association
between number of cells and S-phase proportion, as expected: DNA replication is a
process of quite constant duration because it mainly depends on the species and the
size of the genome. Therefore, the length of the S phase should not depend on the
proliferation status or the size of the cell population, as observed. There is a slight
positive association between cells number and G1/G0-phase proportion. A plausible
biological interpretation is that, at a higher number of cells in a well, the population
tends to reach confluence, a situation in which the cell cycle is arrested and cells are
known to accumulate in phases G0/G1. In addition, we observed stronger depen-
dences between population descriptors. A positive association is observed between
cells number and G2-phase proportion, as well as a negative association between cell
number and M-phase proportion. This is a biological observation which has not been
generally reported, at least to our knowledge. It may be specific to our experimental
design, in which the fields with the highest numbers of cells are reaching the limit
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Table 4.2: Association between population descriptors. Association between cell
count and proportion of cells in different states based on negative controls. The mea-
sure of association is Spearman’s rho and the p-value is computed via the asymptotic
t approximation [54].
S G2 M Apoptosis G0/G1
rho 0.04 0.51 -0.44 -0.09 0.07
p-value 0.144 2e-16> 2e-16> 0.0006 0.01
of confluence, potentially leading to slow the G2 phase and consequently displaying
a reduced number of cells underlying mitosis. Whatever the interpretation of the
above observations might be, these results indicate that the cell descriptors used in
this study present a dependence structure, and this justifies the choice of a model
that can account for this dependency.
Second, we compared the dispersion of fields belonging to the same well to that
of fields randomly selected in the dataset. By dispersion, we mean how close a set
of fields are one to the other. The distance used is the euclidean distance and the
population descriptors used are cell count and proportion of cells in S, G2, M and
apoptotic phases. We scaled the data beforehand and used the measure of dispersion
of multivariate analysis of variance proposed in [4]. This is the sum of squared pairwise
distances. If we consider the set of fields {x1, . . . ,x4}, then the dispersion measure
is:
4∑
i,j=1
||xi − xj||2.
This is equal to the sum of squared distances of each point from the mean, up to a
constant multiplicative factor, and therefore measures how dispersed the fields are.
Figure 4.8 indicates that : (i) fields belonging to the same wells do display some
variability, which should be taken into account by the model, (ii) this variability is
smaller from that of randomly selected fields. Indeed, fields belonging to the same well
are part of the same experiment and therefore, are expected to display less phenotypic
variability than randomly selected fields. Taken together, these two observations are
respectively in good agreement with the ideas of modelling the experimental data
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Figure 4.8: Within population variability. Comparison of the dispersion of fields
belonging to the same wells (boxplot A) and randomly selected fields (boxplot B).
The measure of dispersion is the sum of squared pairwise distances. The population
descriptors (cell count and proportions of cells in S, G2, M and apoptotic states) have
been scaled beforehand.
taking into account (i) “within-population variability” (ii) within a hierarchical model.
Model
The proposed model aims at describing HCS data, i.e. a set of wells, each of them
containing four fields. The input of the method is a representation based on cell
descriptors at the field level (cell count, proportion of cells in S, G2, M and apop-
totic phases in our case), coupled to well assignment information. The output is
an ensemble of population phenotypes (classes) represented by multivariate distri-
butions. To each image (field), the method assigns a distribution over population
phenotypes. We added the quite natural constraint that fields belonging to the same
well should correspond to the same class. This hypothesis allows to take into account
the “within-population variability” in a given well, which should be part of the pop-
ulation phenotype characterization. This is made possible thanks to the hierarchical
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structure of the proposed model.
We tested two different parametrizations for this model : copula-based and gaussian-
based. In the former case, the dependence structure of the multi variate class condi-
tional densities are modelled using a copula independently from univariate marginals
which shape can be chosen separately. Copulas have been studied since the middle of
the 20-th century [40] and have been successfully applied to finance [115], hydrology
[41], meteorology [106], neurosciences [91] or gene expression data [73]. We introduce
copula-based distributions, to build probabilistic densities that represent cell pop-
ulation phenotypic classes. The use of copula for model-based clustering has been
suggested by [60], and proposed by [21] in a semi-parametric framework.
Formulation of the model: We observeXo which is composed ofN wells {X1, . . . ,XN}.
We assume that we haveM fields in each well Xn. Each field is a vector in R
d. There-
fore we represent each well Xn by a M -tuple of vectors Xn = {xn1, . . . ,xnM} where
xni ∈ Rd for n = 1 . . .N and i = 1, . . . ,M . In our application, we have d = 5 and
M = 4. The components of this representation are cell counts and proportions of
cells in different phases of the cell cycle. In order to model different classes of wells,
we introduce the latent variable Z ∈ {1, . . . , K} associated to each well where K is
fixed in advance. We also assume that given the value of Z, the fields belonging to
one well are independent and that wells are independent and identically distributed.
These are typical assumptions made in graphical models literature. If Θ represents
the parameters of this model, the density associated to Xn = {xn1, . . . ,xnM} is then
P (Xn|Θ) =
K∑
Z=1
P (Z|Θ)
M∏
j=1
P (xnj|Z,Θ) (4.3)
With this definition, the likelihood of the total dataset Xo becomes
P (Xo|Θ) =
N∏
n=1
P (Xn|Θ) =
N∏
n=1
K∑
Z=1
P (Z|Θ)
M∏
j=1
P (xnj|Z,Θ) (4.4)
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Given Θ, this model can be viewed as a generative process which explains how to
generate the data from a probabilistic point of view. To generate a cell population (a
well Xn), this process takes the following form:
• Choose a population phenotype (a class) from a fixed list. This amounts to
sample Z ∼ P (Z|Θ).
• Given the population phenotype, generate several sub-populations (fields) ac-
cording to the multivariate distribution related to this population phenotype.
This amounts to sample for 1 ≤ j ≤M , xnj ∼ P (xnj|Z,Θ)
Given P (Z|Θ) (a multinomial) and the class conditional density P (xnj|Z,Θ), the
main issue is to perform inference and learning, which is reversing the generative pro-
cess defined above to estimate the class distribution related to each well, P (Z|Xn,Θ)
, and estimate the parameters of the distributions representing phenotypic classes.
We propose gaussian class conditional distributions and copula-based distributions
which we now describe.
Copula-based class conditional distributions: Copulas became popular in sta-
tistical literature at the end of the twentieth century. However, the study of these
probabilistic objects goes back to the middle of the century, see [88] for a general
review about copulas. The usefulness of copulas comes from Sklar’s theorem which
states that multivariate distributions can be formalized in term of copula and uni-
variate marginal [110] (see also appendix A).
We use the gaussian copula family which has been introduced in 2000 by [132].
We use the density function formulation of these copulas which let us work with
probabilistic densities. A gaussian copula density function is parametrized by a cor-
relation matrix R. We refer to the gaussian copula density function as cgR. Let
{Fθ1 , . . . , Fθd} be a set of univariate marginal distributions, {fθ1 , . . . , fθd} the corre-
sponding univariate densities, such that θi ∈ R+∗ × R+∗ for all i. We parametrize
fθ1 as a gamma distribution with parameters {θ11, θ12}. This is a distribution over
strictly positive numbers which represents cell counts here. Moreover, we parametrize
fθi , i > 1 as a beta distribution with parameters {θi1, θi2}. This is a distribution
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over (0, 1) which represents proportions of cells showing different cellular phenotypes.
Plugging these marginals in the gaussian copula cgR, whose correlation matrix is R,
allows to parametrize a distribution whose support is exactly the one our variables
are limited to, and to model the dependence structure between univariate marginals.
If x = (x1, . . . , xn) ∈ R+∗ × (0, 1)d−1, it takes the form:
P (x|R, θ1, . . . , θd) = cgR(Fθ1(x1), . . . , Fθd(xd)|R)
d∏
j=1
fθi(xi)
Moreover, we notice that such a parametrization of the class conditional distribution
involves exactly the same number of parameters as a standard gaussian model: one
correlation matrix and two parameters per univariate marginal. For copula-based
densities, standard parameter estimation by maximum likelihood [25] requires com-
putationally intensive numerical optimization. Approximations of this procedure have
been proposed to avoid this. Among them, inference function for margin [109, 63]
consists in estimating univariate marginal parameters first and to estimate copula
parameters given the marginal parameters in a second step. A semi-parametric pro-
cedure [40] has been proposed. This is similar in spirit, except that a non parametric
estimate of the univariate marginal distribution function is used (normalized ranks)
before estimating the copula parameters based on these non parametric estimates.
We used the latter method to estimate copulas parameters together with standard
univariate maximum likelihood estimates for marginals. [72] observed empirically
that this procedure is more robust to marginals misspecification than the standard
maximum likelihood and inference functions for margin. Moreover, this method is
less computationally intensive than the two former ones. Details about parameter
estimation procedures are provided in appendix A.
Inference and learning: Assume that we have a parametrized class probability
distribution P (Z|Θ) (a multinomial) and a class parametrized conditional distribution
P (x|Z,Θ), gaussian or copula-based in our case. Finding the best parameters for our
mixture model amounts to maximize (4.4) or the logarithm of (4.4). Optimizing this
objective with respect to Θ is made difficult by the presence of a sum over latent
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classes. Approximate inference has shown to be efficient in this kind of setting. [66]
provides a general framework for EM type inference among others (see also chapter
2), which we used to learn the parameters of the model and to infer phenotypic classes
of wells in our dataset. Sufficient statistics can be used in the gaussian case. In the
copula based model case, we implemented the semi-parametric estimation procedure
of [40]. The maximization step is very similar to standard maximization step for
Gaussian mixture models. First, univariate marginals parameters are estimated using
sufficient statistics and second, correlation matrix of copulas are estimated using
scaled ranks instead of absolute values of marginal variables. After optimizing the
model parameter Θ, we obtain K classes represented by class proportions P (Z|Θ)
and class distribution P (x|Z,Θ). Each well X can be represented as a mixture of cell
population phenotypes given by P (Z|X,Θ), which is inferred during the optimization
process.
Baseline comparison: The proposed model accounts for “within population vari-
ability” through its hierarchical structure and “dependence structure of cell popula-
tion descriptors” through multivariate probability distributions that model depen-
dence between variables. Those two aspects of the model are motivated by obser-
vations arising from the data. In order to validate those hypotheses, we compare
the performances of those two models to a standard gaussian mixture model with
diagonal correlation matrices. This model does not take into account the fact that
different fields come from the same well. It also assumes an absence of dependency
between population descriptors, because the gaussian class conditional distribution
covariances matrices are constrained to be diagonal.
4.3.3 Results
Data was generated from a siRNA based HCS on a Ewing sarcoma derived cell line.
The considered population descriptors were cell count and proportion of cells show-
ing different cellular phenotypes (S, G2, M phase or apoptotic state). From these
data, positive and negative siRNA controls were used in this work to illustrate our
approach. GL2 siRNA is a negative control that does not affect proliferation and
4.3. CELL POPULATION PHENOTYPING 87
cellular phenotypes. KIF11 siRNA is a positive control that induces cell death and
therefore leads to massive alteration of cellular phenotypes.
As presented in the “Preliminary data analysis” of Materials and Methods section,
we observed that the population descriptors displayed a dependent structure, and
that fields belonging to the same well presented less dispersion than fields randomly
selected from the dataset (see Figure 2). These preliminary results justify the use of
the proposed gaussian or copula based hierarchical models.
We first compare the gaussian and copula based parametrizations of the model
in terms of model fitting and generalization properties (See model fitting section).
Once parameters of the model are fitted to the data, we build an object representing
the density of the data we considered. This is useful in term of novelty discovery. In
our case, it would correspond to finding cell populations that are different from the
negative control population (GL2 silencing siRNA transfected cells), which behaviour
is supposed to be hardly affected by this transfection. Confronting a test dataset to
the model, evaluating the likelihood of this new data with respect to this model,
allows to measure how different from the training set the test set is. We observe that
the proposed method allows to separate positive and negative controls (see section
“Novelty detection and positive controls”).
Moreover, given the training set, the model classes define the population phe-
notypes and account for the joint distribution of cell population descriptors. We
investigate the properties of these phenotypic classes and underline that the cop-
ula based parametrization extracts more meaningful phenotypic classes (see section
“Model classes as population phenotypes”). Moreover, we show how those population
phenotypes account for different cell behaviours by relating the population phenotypes
to cellular phenotypes (see section “Relation between population phenotypes (classes)
and cellular phenotypes”).
We discuss the advantage of the proposed model compared to previous approaches
focusing on one specificity of the approach, “within-population variability” consider-
ation (see section accounting for “within population variability”). We first describe
the cross validation experiment that was carried out to evaluate properties of the
model.
88 CHAPTER 4. PHENOTYPIC RESPONSE
Cross validation
We performed 5-fold cross validation experiments on the negative controls dataset
composed of 336 wells which represents 1344 fields. This set is split into five subsets
of roughly equal sizes. Each subset is taken in turn as a test set, the model is trained
on the remaining four sets, and the likelihood of the test set is then evaluated with
respect to the model built with the training set. Because the optimization result
relies on the initial parameter value, we performed five random restarts for each fold.
This allows to evaluate the generalization performances of the model for the whole
dataset. We performed this experiment for the gaussian and copula-based models,
as well as the baseline model, for a number of population phenotypes ranging from 2
to 20. The number of classes is a parameter of the proposed method. We repeated
this experiment ten times over different splits of the dataset. The model giving the
best generalization property, i.e. the model with the highest test likelihood, was
then trained on the whole negative controls set and the corresponding classes were
analysed.
Model fitting
The cross validation experiment allows to compare different model performances on
this dataset. Because all the proposed model are probabilistic in nature, the first
criterion we choose to compare different models is the likelihood computed for a test
dataset . We proposed two parametrization of the mixture models, a gaussian and a
copula-based parametrization which we review in the method section. We compare
those two parametrization to the baseline model using this criterion .
Figure 4.9-a shows the training log likelihood of the two models and the baseline
model for different numbers of classes. This training likelihood was evaluated using
the whole training set. It appears that the copula-based model results in a higher
value of the training likelihood. This observation is valid for the whole range of
number of classes we considered. It also appears that the baseline fits much less to
training data .
Figure 4.9-b represents the test log likelihood, evaluated by cross validation, for
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the two models with different numbers of classes. Again, it appears that the copula-
based model has better generalization properties independently from the number of
classes. Here again the baseline model provides worse fit on test data .
This experiment shows that the proposed model outperforms the baseline model on
both training and test datasets for both gaussian and copula based parametrization.
This observation validates assumptions encoded in the model which we referred to as
“dependence structure of population descriptors” and “within-population variability”.
We consider now comparing in more details the two parametrizations of the proposed
model.
The copula-based model outperforms the gaussian model providing better fit on
training data and higher generalization properties on the negative control dataset,
while involving exactly the same number of parameters. The copula-based density
support matches the domain where our dataset is spread, while the gaussian support
is the whole space. Similar results have been reported in other comparative studies
of copula models based on different datasets: [32] is an example.
Based on these results, we pick up the model providing the best generalization
performances and fit it to the whole negative control set, restarting randomly the
algorithm 10 times to avoid local optimum for the parameters values. The results are
presented in the two following sections.
Novelty detection and positive controls
One of the objectives of modelling the negative controls density is to show that we
can detect cell populations that are different from these controls, because they could
correspond to experiments that are relevant for the studied biological question. To
illustrate this point, we used, as controls, cell populations that were transfected with
a KIF11 silencing siRNA. We refer to these cell populations as positive controls. It is
known that these controls should have a very different behaviour compared to negative
controls. Panels (a) to (e) in Figure 4.10 represent the densities of positive and
negative controls univariate cell population descriptors averaged over wells. Panel (f)
in Figure 4.10 represents the densities of positive and negative control log likelihood.
Here the model is trained on negative controls.
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Figure 4.9: Model fitting. Train (a) and test (b) log likelihood of the negative
control data for the two proposed models, and the baseline, varying the number of
phenotypic classes. Green corresponds to the copula based model, red corresponds
to the gaussian model, and black corresponds to the baseline model. For training
log likelihood, we picked the best model among 10 random restarts of the algorithm.
For the test log likelihood, the boxes account for the variability among ten different
splits of the data in a cross validation setting. Given a data split, for each fold and
each number of classes, we picked the best model among 5 random restarts of the
algorithm.
Positive controls are found to be very different from negative controls. It is easy
to distinguish them from negative controls only looking at cell count, for example.
The panel (f) in Figure 4.10 represents the distribution of log likelihood over wells.
The log likelihood given by the model separates the two types of controls. Training
our multivariate model on negative controls and testing it on experiments is not less
powerful than using univariate methods.
Model classes as population phenotypes
We propose to use several densities in a mixture model to define population pheno-
types by the classes of the model, which corresponds to a mathematical definition.
The number of classes was chosen by cross validation.
We inspected the univariate marginal densities. Figure 4.11 compares the em-
pirical density and the density fitted by the model for one population descriptor,
proportions of apoptotic cells, for two phenotypic classes. We notice that the model
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Figure 4.10: Novelty detection and positive controls. Density plot of cell population
descriptors averaged over wells (panel (a) to (e)) and log likelihood (panel (f)) given
by the model trained on negative controls. Positive controls are very different from
negative controls. It is easy to distinguish them from negative controls only looking at
cell count. The log likelihood given by the model separates the two type of controls.
We observe that the discriminative power of the univariate descriptors is not lost
when considering the model likelihood.
densities fitted by the copula model are closer to the empirical density compared to
those fitted by the gaussian model. In addition, the parameters of the copula distri-
butions represent physically valid distributions. For example, proportions of cells in
apoptosis is higher than 0. As shown in Figure 4.11, the copula-based model accounts
for this, while the gaussian model does not.
One example of use of the classes proposed by our model is the detection of
atypical behaviours in the training set. Indeed, we inspected visually the cell images
of negative control wells that were found in classes containing very few wells (3 classes
with 5, 6 and 9 wells respectively over a total of 336). We found that 17 among
these 20 wells were not relevant for the negative control modelling because they were
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Figure 4.11: Model and empirical distributions. Examples of classes found by the
model (Copula model on the left, gaussian model on the right). The proportion
of cells in apoptotic state is represented for the cell populations belonging to these
classes. We compare for two classes the univariate marginal densities. For each class,
the empirical density is represented with a solid line and the density fitted by the
model is represented with a broken line.
experimental outliers. These wells presented a recurrent atypical behaviour, and
therefore, a few small classes were inferred to account for this during the learning
procedure. Figure 4.12 shows bivariate scatter plots of the negative control fields and
with these outliers. The proposed method provides clues for detection of such cases.
Moreover, we observed that the other classes containing a higher number of wells
could account for experimental variability over cell populations. For example some
particular classes contained mainly fields in which cell populations had reached con-
fluence, while others did not, as we could observe in the corresponding images. All the
classes do not necessarily account for biologically interpretable differences, because
the diversity of cell population showing the same behaviours may require several
classes to model it accurately. The number of classes was inferred based on cross
validation generalization accuracy which is a much more objective criterion.
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Figure 4.12: Negative control outliers. Bivariate scatter plots of negative controls.
The red points correspond to fields belonging to small classes. They were indeed
considered as outliers after checking the images (they were found to be irrelevant).
Enough of these wells were present in the dataset so that separate classes were inferred
by the model to account for this atypical behaviour.
Relation between population phenotypes (classes) and cellular phenotypes
We considered negative controls and removed the outlier classes since, as mentioned
above, they corresponded to irrelevant fields. We inspected differences between re-
maining classes based on the population descriptors (which were defined from cellular
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phenotypes), because this could provide some clues about the biological interpretation
of population phenotypes. Figure 4.13 represents the field distribution of population
descriptors for each class. It shows that each population descriptor can separates
some of the classes, but that none of the descriptors separates all of the classes on its
own. This suggests that there is no redundancy between the population descriptors
and that the classes reflect possible combinatorial association between population de-
scriptors. The multivariate character of the proposed model allows to account for this
fact, while it would not be possible using each population descriptor individually.
Accounting for “within population variability”
HCS experiments do not provide an average behaviour characterization, but a whole
panel of cell responses within different sub populations (fields) taken from the same
well. This information is much richer than a simple average response. The data ac-
count for the variability of the responses within a given population. As observed in
section 4.3.2, this variability is not the same as the global field variability. The hier-
archical structure of the model allows to take this into account which cross validation
suggested to be a correct modeling assumption. Indeed, since all fields of a given
well correspond to the same experiment, we therefore impose that they belong to
the same phenotypic class. The corresponding density must account for the observed
variability between those fields.
We illustrate this point in Figure 4.14 which compares one particular negative
control well with the whole set of negative controls. Vertical red bars represented in
Figure 4.14 show that population descriptors averaged over wells do not account for
field variability (see Figure legend). Looking at panel (a) to (e) and blue vertical
lines, the well looks similar to the majority of the negative controls. This would
correspond to the single descriptor averaged over wells approach. However the red
bars in those panels show that there is a lot of variation between the fields taken from
this well, and some fields actually fall in tails of the distribution. This is reflected in
the (f) panel where the vertical blue line is close to the tail of the distribution. Thus
the methods could help to eliminate a potential experimental bias while a simpler
approach would not.
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Figure 4.13: Relation between classes and population descriptors. The classes are
represented on the x axis. For each class, the boxplot shows the distribution of
population descriptors among the fields of this class. Outlier classes were removed.
The cell count descriptor has a similar distribution for classes 2 and 3, but other
descriptors also allow to differentiate them. Similarly, classes 3 and 5 have a similar
proportion of apoptotic cells, but other descriptors also allow to differentiate them.
More generally, each descriptor separates different classes. This suggests that there
is no redundancy between population descriptors, and that the classes reflect the
combinatorial association between population descriptors.
4.3.4 Conclusion and discussion
In this section, we tackled the cell population phenotyping step in the HCS data
analysis framework. This step is performed after image segmentation and cellular
phenotyping (steps 1 and 2). It aims at comparing experiments, and gathering cells
with similar behaviours in the same class (i.e. assigning them to the population
phenotype). The main difficulties in achieving this task are linked to “dependence
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Figure 4.14: Example of a well. Panels (a) to (e), the density plots represent
the distribution of cell population descriptors averaged over wells for the negative
control dataset. Red lines are the values of the 4 fields of the considered well and
the blue lines are the population descriptors averaged over the 4 fields. Panel (f)
represents the density of the log likelihood for all negative controls. The blue vertical
line represents the log-likelihood of the considered well.
structure of population descriptors” and “within-population variability” which should
be taken into account. Simple observations showed that these are naturally occurring
facts observed in our HCS data. The necessity to take them into account precisely
come from the fact that we are considering populations of cells as systems which are
groups of smaller species (cells) and which organization is part of the characterization
of the behaviour at the population level.
We implemented and compared the performances of two different parametriza-
tion of a mixture model, and baseline model that does not account for the specific
aspects of the data underlined above. This was performed based on a dataset com-
prised of two types of cell populations. A comparison of model fitting on test data,
using cross validation, suggest that the two specific aspect of the data we focused
on when building the model should be considered when studying this kind of data.
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Moreover, the copula-based parametrization of the proposed model outperforms the
gaussian parametrization. However this copula-based model has some disadvantages
from the computational point of view, model fitting being much slower and requiring
approximations compared to the gaussian formulation.
The main features of cell populations that the model is able to describe are:
• Univariate variables (cell count or cellular phenotype proportions in our case),
described by parametric densities
• Multivariate dependence structure, described by a copula
• Variability within a cell population, described by the hierarchical structure of
the mixture model
These features constitute the specificity of HCS data. The proposed model takes
them into account to build a phenotypic characterization at the population level.
Cross validation experiments suggest that taking into account these aspects of the
data provides better models. The literature is very scarce regarding population phe-
notypes definition. To our knowledge, none of the proposed methods take into account
the “within-population variability”, which underlines the originality of the proposed
model. Pushing this idea further, a future line of work includes modelling at the cell
level. [111] propose to infer cell classes from HCS data using single cell measurement.
A future work direction is to add a level in the model to infer cell phenotypic classes
and population phenotypic classes at the same time in a global model. However the
inference computational cost increases a lot and online inference should be used such
as in [52].
One application of this model is novelty detection, which is measuring how a
cell population related to a given experimental condition is different from a control
population. Once a control density is estimated, one can attribute a likelihood to
each test experiment which allows to rank them according to how different they are
from the controls. For example, the model can detect which siRNA phenotypes are
different from a set of controls, and provide orientations toward the most relevant wells
in a set of test experiments. The present work constitutes a preliminary validation of
this procedure based on two limit cases.
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Moreover, the method can help gathering cell populations that show similar be-
haviours into phenotypic classes. We observed that it can be useful for detection of
irrelevant pictures gathered in separate phenotypic classes. The most important fu-
ture work is to assess to which extend the inferred phenotypic classes are biologically
meaningful. For example, wells in which siRNAs target genes with similar biological
functions or incubated with drugs with the same target should belong to the same
phenotypic class. Future work also include application of the model to target identifi-
cation. This would require further experimental study for the validation of potential
target genes.
Chapter 5
Dynamical system parameter
identification under budget
constraints
Re´sume´
Le point de vue adopte´ dans ce chapitre se situe a` l’interface entre l’e´chelle mole´culaire
conside´re´e au chapitre 3 et l’e´chelle phe´notypique pre´sente´e au chapitre 4. Nous
nous inte´ressons ici aux comportements dynamiques e´mergeant d’inte´ractions non
line´aires entre des espe`ces mole´culaires. Ces proprie´te´s dynamiques sont cepen-
dant trop abstraites pour eˆtre traite´es comme des phe´notypes. Le proble`me con-
side´re´ est l’identification de parame`tres d’un syste`me dynamique et la construc-
tion d’un plan d’expe´rience afin de faciliter cette identification. Tous les re´sultats
pre´sente´s se basent sur des simulations nume´riques, la strate´gie d’identification ainsi
que la dynamique mole´culaire d’un re´seau d’interactions sont simule´s afin de com-
parer diffe´rents choix strate´giques. Nous discutons l’importance de de´finir des crite`res
nume´riques bien fonde´s dans le contexte de la recherche du meilleur plan d’expe´rience.
Une strate´gie ge´ne´rale pour attaquer ce proble`me est pre´sente´e et une imple´mentation
nume´rique de cette strate´gie est propose´e. La comparaison de diffe´rentes approxima-
tions nume´riques est donne´e ainsi que les re´sultats du challenge DREAM 7 “Network
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Topology and Parameter Inference” pour lequel la me´thode a e´te´ conc¸ue initialement.
Le contenu de ce chapitre n’a pas encore e´te´ publie´.
Abstract
The point of view adopted in this chapter lies between the molecular scale treated
in chapter 3 and the phenotypic scale presented in chapter 4. We are concerned
with dynamical behaviours emerging from non linear interactions between molecular
species. These dynamical properties are too abstract to be considered as phenotypes.
The problem is to identify unknown dynamical parameters and to design experiments
that make this identification more efficient. All the results presented are based on
numerical simulations, both the identification strategies and the molecular dynamics
of a relatively small interaction network are simulated to compare different strategical
choices. We discuss the necessity to provide well defined numerical criteria in order to
optimize experimental design. A general strategy to tackle this problem is presented
and a numerical implementation of this strategy is proposed. Comparison of different
numerical approximation is provided as well as results from the DREAM 7 Network
Topology and Parameter Inference Challenge results for which this method was ini-
tially designed. The material presented in this chapter has not yet been published.
5.1 Introduction
Systems biology emerged a decade ago as the study of biological systems in which
interactions between relatively simple biological species (genes, proteins, metabolites
. . .) lead to overall complex behaviours [74]. Such studies require to specify network
structure and dynamical models. Typical descriptions of the dynamics of the system
can be stochastic or deterministic [130]. Both descriptions involve unknown param-
eters. This motivates the design of methods that optimize the choice of experiments
to be conducted in order to estimate unknown parameters from data [81]. Sequential
methods constitute a promising line of research for these questions [62], a problem
which is very close in its formulation to the active learning problem [107].
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Various methods have been proposed for sequential experimental design in systems
biology [62, 122, 9, 10, 116]. Most of them only take into account local uncertainty
about parameters true values, i.e. strong multi-modality of the objective function is
not considered. As pointed out in the literature, this is a very challenging inverse
problem and it might even be pointless from a dynamical point of view [97], or from
a biological point of view [34] when applied to real data. Indeed, it is shown in [97]
based on numerical simulations on molecular biology dynamical systems that widely
different parameter values produce very similar dynamical behaviours. Moreover [34]
show based on real time course data that using inverse problem methods to estimate
a unique parameter vector produces values which are biologically meaningless.
5.1.1 Evaluation of experimental design strategies
The experimental design problem considered in this chapter is broader than the pa-
rameter estimation problem. It relies on the ability to estimate parameters accurately.
In addition, the design of experiments requires to figure out how further experiments
could mitigate uncertainty and under-determinedness of the system. The perfor-
mances of a strategy regarding this problem are difficult to evaluate. Moreover,
different strategies might perform differently on different dynamical systems. It is
therefore crucial to be able to evaluate, simulate the experimental design process in
order to choose a relevant strategy when faced with a problem of this type.
As a consequence, proposing a strategy that could be reproducibly evaluated based
on simulations requires the design choices to rely on well defined numerical criteria.
The design strategy proposed in this chapter relies on numerical approximation of a
unique numerical criterion. Therefore, it is possible to carry out simulation of the
design process and compare different numerical approximation schemes based on this
criterion.
5.1.2 Proposed strategy
This work is motivated by DREAM7 Network Topology and Parameter Inference
Challenge [1, 2] which focuses on ordinary differential equation parameters estimation
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from in silico experiments with budget constraints (i.e. limit of the quantity of data
one has access to). This challenge is a simulation of an experimentation process in the
context of systems biology. One has to estimate dynamical parameters of a system
and can require to perform experiments on this system with different costs. The
objective is to estimate the parameters as well as possible given a fixed budget by
choosing sequentially experiments to be performed on the system to get new data.
We propose a strategy adapted from active learning paradigm [100] which can be cast
in the Bayesian framework of [81] for experimental design. This formulation has two
appealing conceptual advantages:
• We provide a unique numerical criterion to discriminate between several exper-
iments
• Bayesian paradigm relies on distributions over parameter space instead of a
single value
The motivation behind the first idea is to construct a method that can be com-
pletely automatized without any human intervention. The focus is not on being
optimal for a specific problem instance, rather on the generality of the method to
make it easier to transpose to other problems and to make it potentially usable on
large scale problems which sizes do not allow to deal with systematic human interven-
tion. The second idea is motivated by the remarks of [97, 34] which were presented
in the beginning of this introduction.
5.1.3 Content of the chapter
DREAM7 challenge was the occasion to implement this formulation and compare
it to other methods. In addition, we implement a fully automatized simulation of
the experimental design process. This allows to make extensive comparisons be-
tween different space search procedures and to compare with a blind random design
strategy. We underline that this is a necessary condition to provide reproducible com-
parison between different strategies. As our results suggest, the proposed strategy
reproducibly outperforms random design. Moreover, exploring several modes of the
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Figure 5.1: Gene network for DREAM7 Network Topology and Parameter Inference
Challenge. Promoting reactions are represented by green arrows and inhibitory reac-
tions are depicted by red arrows.
objective function has a large impact on the performance leading to results that are
more reproducible.
To summarize, we describe an implementation of a general scheme that could in
theory be applied to other dynamical system parameter estimation problems under
budget constraints. The procedure can be completely automatized which allows to
compare different strategies and verify the reproducibility of the results. Finally, we
question the approach of parameter inference and present a slightly different perspec-
tive on the problem of dynamics characterization.
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5.2 Methods
5.2.1 In silico network
We took part in the first challenge of DREAM7 Network Topology and Parameter
Inference Challenge and used the system provided to carry out our experiments. The
network is composed of 9 genes. We were provided with the complete network struc-
ture, including expression of the kinetic laws governing the dynamics of this network
for which parameters had to be estimated. For each of the 9 genes, both protein
and messenger RNA were explicitly modelled and therefore the model contained 18
continuous variables. Promoter strength controls the transcription reaction and ribo-
somal strength controls the protein synthesis reaction. Decay of messenger RNA and
protein concentrations is controlled through degradation rates. A complete descrip-
tion of the underlying differential equations is found in appendix B. The complete
network description and implementations of integrators to simulate its dynamics are
available from [2]. A picture of the network is provided in figure 5.1. Promoting
reactions are represented by green arrows and inhibitory reactions are depicted by
red arrows.
Various experiments can be performed on the network producing new time course
trajectories in unseen experimental conditions. An experiment consists in choosing
an action to perform on the system. The possible actions are
• Nothing (Wild type)
• Delete a gene (remove the corresponding species).
• Knock down a gene (increase the messenger RNA degradation rate by ten folds).
• Decrease gene ribosomal activity (decrease the parameter value by 10 folds).
These actions were coupled with observable quantities
• Messenger RNA concentration for all genes at two possible time resolutions.
• Protein concentration for a pair of proteins at a single resolution.
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Purchasing data consists in selecting an action and an observable quantities. In ad-
dition, it was possible to estimate the constants (binding affinity and hill coefficient)
of one of the 13 reactions in the system. Different experiments and observable quan-
tities have different costs, the objective being to estimate unknown parameters as
accurately as possible, given a fixed initial credit budget.
Notations
Model parameters are denoted by θ ∈ Rp. e denotes an experiment to be performed,
i.e. choice of a specific perturbation. The choice of one parameter value θ and exper-
iment e leads to time trajectories which we denote by Y (θ, e). In our case, they are
positive quantities since we consider concentrations of chemical species. In practice,
we can obtain them using differential equation solvers. The underlying dynamical
system does not play a significant role here and we consider that the only access
we have to it is through Y (θ, e). In addition to perturbation, we need to choose an
observable obs from a set of observables O. The point here is that we cannot observe
the whole system in one experiment, and in particular, we cannot observe the whole
set of time trajectories Y (θ, e). We only have access to a subset of these trajectories
discretized with respect to time at a given resolution. The choice of an observable
obs leads to an observations o which is a noisy realization of a sub-part of the true
underlying dynamical system Y (θ∗, e) where θ∗ is an unknown parameter. The prob-
lem is to choose a series of experiments and observables in order to infer θ∗ as well as
possible, given the cost constraints.
Model
P denotes a likelihood model related to a single experiment. Roughly speaking, for a
given parameter value θ, experiment e and observable obs, P (o|θ, e, obs) reflects how
well data o fits to Y (θ, e). In our setting, the noise model was specified by challenge
organisers and we took the corresponding likelihood to model data (heteroscedastic
Gaussian noise which variance is an affine transform of the mean value, see the chal-
lenge web page for details). If we have K experiments e1, . . . , eK and observables
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obs1 , . . . , o
bs
K with corresponding observations o1, . . . , oK , the joint likelihood function
has the form:
P (o1, . . . , oK |θ, e1, . . . , eK , obs1 , . . . , obsK) = P (o1|θ, e1, obs1 )× . . .× P (oK |θ, eK , obsK)
(we assume independence of noise realizations). We denote by π0 a prior distribution
over parameter space Θ. We define sequentially πK to be the posterior distribution
over model parameters when we get data from experiments 1 to K,
πK(θ) = P (θ|o1, . . . , oK , e1, . . . , eK , obs1 , . . . , obsK) (5.1)
∝ π0(θ)× P (o1, . . . , oK |θ, e1, . . . , eK , obs1 , . . . , obsK)
∝ πK−1(θ)× P (oK |θ, eK , obsK).
Risk function
We focus on parameter inference. Let θ∗ ∈ Θ ⊆ Rp denote the true model parameters
and θ another parameter value. We implemented the risk used by challenge organizers
to evaluate parameter estimates, namely r(θ∗, θ) =
∑p
i=1 log(
θi
θ∗i
)2. We do not have
any access to the true model parameters, but we can estimate posterior distributions
related to it. Given such a distribution π, we define the expected risk at θ0 by
R(θ0, π) = Eθ∼πr(θ, θ0).
Sequential experimental design
The purpose of the proposed framework is to choose experiment e and observable obs
in an optimal way, and iterate. The proposed methodology is very close in spirit to
that proposed in [81]. However, the design is made sequentially in a greedy fashion,
and not globally, because of high computational cost. Although the setting is slightly
different, the proposed methodology can be viewed as an application of the strategy of
[100] using a loss that is adapted to our setting. Formally, at each step k, we have the
knowledge of e1, . . . , ek, o
bs
1 , . . . , o
bs
k , o1, . . . , ok which defines a posterior distribution πk
on the parameter space Θ as given in (5.1). Given θT parameter values, an experiment
e and an observable obs, we note o ∼ PθT ,e,obs to define that o follows the distribution
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which density is P (o|θT , e, obs) as given by our likelihood model. We denote by πo the
posterior probability over parameter space given the observation o. Next perturbation
ek+1 and observable o
bs
k+1 are chosen such that:
(ek+1, o
bs
k+1) = argmin
e,obs
EθT∼πkEo∼PθT ,e,obs
R(πo, θT ) . (5.2)
where πo(θ) ∝ πk(θ)×Pθ,e,obs(o). This formulation follows the principle of integrating
out what is unknown, namely the true parameter value and the noise. If different
experiments and observables have different cost Ce,obs , then we can choose the com-
bination with the largest marginal expected risk reduction. In this case, we have:
(ek+1, o
bs
k+1) = argmax
e,obs
EθT∼πkEθ∼πkr(θT , θ)− EθT∼πkEo∼PθT ,e,obsR(πo, θT )
Ce,obs
. (5.3)
In both cases, the most important task is to estimate the expected risk for unseen
experiments and observable combinations. Given an experiment e and observable obs,
in order to estimate the expected risk of this combination, we consider all θT ∈ Θ
and estimate the risk related to each of them if it was the true parameter value,
integrating out noise. We then integrate out θT and choose the best combination.
Choosing the next experiment according to this procedure would require to compute
a triple expectation which is of course not tractable analytically. This formulation is
general and provides an objective criterion that could be applied to many different
problems. However, implementing this method requires very strong approximations
where algorithmic details play an important role.
5.2.2 Implementation
We denote by E1, . . . , EN , the set of possible future actions. In general, Ei describes
a perturbation e of the system and an observable obs. At each iteration K, we have
the knowledge of the past, o1, . . . , oK , e1, . . . , eK , o
bs
1 , . . . , o
bs
K . This defines posterior
distribution over parameter space πK . This distribution cannot be directly manip-
ulated and needs to be approximated in some way. For this, we rely on sampling.
The two building blocks of the method are sampling from πK given the past (a brief
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introduction to sampling is given in chapter 2), and evaluating the risk of each sample
point. Algorithm 1 summarizes the procedure to choose the next action. We note
that the structure of the algorithm is very similar to what is proposed in literature
(e.g. [62, 122, 9, 10, 116]), we first evaluate parameter uncertainty given the data at
hand and then optimize the choice of the next experiment given this uncertainty. The
specificity of the proposed scheme is that it takes advantage of the theoretical and
practical tools available for Bayesian inference. Moreover, a unique numerical crite-
rion is used to discriminate between experiments. This criterion is based on expected
risk and, by construction, takes interactions between all components of the problem
into account. An illustration of this fact is given in section 5.3.1.
Algorithm 1: NextExperiment
input : o1, . . . , oK , e1, . . . , eK , o
bs
1 , . . . , o
bs
K , {E1, . . . , EN}
output: eK+1
begin
Θ ← sample(πK)
for e ∈ {E1, . . . , EN} do
for θT ∈ Θ do
RθT ← evalRisk(θT)
Re ← mean(RθT |θT ∈Θ)
eK+1 ← choose({Re})
Practical details
We implemented the proposed strategy using the same noise model and risk function
that were used to evaluate candidates in the DREAM7 Network Topology and Pa-
rameter Inference Challenge [1, 2]. This section describes approximations that were
made in our implementation of the proposed strategy. As we mentioned in previous
sections, the problem cannot be solved exactly and these approximations are needed
to apply our strategy. They could be replaced by other approximations. The appeal-
ing specificity of what is proposed here is that one uses the same sample to estimate
the current posterior and the expected risks of all possible actions at each step of
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algorithm 1. We refer the reader to [5] for an introduction to sampling schemes and
to [90] for a description of finite difference approximation and BFGS algorithm. A
brief introduction to sampling approximations is given in chapter 2.
Enforcing regularity through the prior distribution
Evaluation of parameter likelihood requires to solve several initial value problems.
We used the implementation of the method proposed in [15] provided in the package
[114]. The prior distribution π0 plays a crucial role at early stages of the design
when no data is available about many aspects of the system’s behaviour. It penalizes
parameters leading to dynamical behaviours that we consider unlikely. In addition
to a large variance log normal prior, we considered penalizing parameters leading to
non smooth time trajectories. This is done by adding to the prior log density a factor
that depends on the total variation of time course trajectories. The advantage of this
is twofold. First, it is reasonable to assume that variables we do not observe in a
specific design vary smoothly with time. Second, this penalization allows to avoid
regions of the parameter space corresponding to very stiff systems, which are poor
numerical models of reality, and which simulation are computationally demanding or
simply make the solver fail. This is very beneficial to guide the search in the sampling
phase.
Sampling from posterior distribution
The likelihood surface shows multi-modality, plateaus and abrupt jumps as illustrated
in figure 5.2. Traditional sampling techniques tend to get stuck in local optima, not
accounting for the diversity of high likelihood areas of the parameter space. Finite
difference calculation allows to compute an approximation of the gradient of the log-
likelihood function which is used together with BFGS algorithm to find local maxima
of the posterior distribution. Finite difference approximation is known not to be the
most stable numerical method for gradient computation. However, this is the method
that provided us with the best trade off between computation, sample size, sample
diversity and data fitting. In order to ease sampling, we use a local search method
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Figure 5.2: Log likelihood surface for parameters living on a restricted area of a two
dimensional plane. For clarity, scale is not shown. Areas with low log-likelihood
correspond to dynamics that do not fit the data at all, while areas with high log-
likelihood fit the data very well. The surface shows multi-modality, plateaus and
abrupt jumps which makes it difficult to sample from this density. When parameters
do not live on a plane, these curses have even higher effect.
to provide an initial value for a Metropolis Hastings sampler (see also chapter 2).
We combine isotropic Gaussian proposal and single parameter modifications. This
strategy can be repeated several times to get samples from different modes.
Estimating the expected risk
Experiments that provide a time course output: suppose that e is a pertur-
bation of the system and obs is an observable. The risk related to this experiment is
expressed as:
R = EθT∼πKEo∼PθT ,e,obs
Eθ∼πor(θ, θT )
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where πo(θ) ∝ πK(θ)×Pθ,e,obs(o). Suppose that we have a sample Θ, of size N , drawn
from πK . Choosing the next experiment requires to compute Eo∼P
θT ,e,o
bs
Eθ∼πor(θ, θT )
for each θT ∈ Θ. For a fixed θT , the output variable o is random. The inner expecta-
tion can be approximated by importance weighting:
Eθ∼πor(θ, θT ) ≃
∑
θ∈Θ
wo(θ)r(θ, θT )
where wo(θ) ∝ P (o|θ, e, obs) (prior terms cancel out, see also chapter 2). It is impor-
tant to normalize these weights correctly since dimensionality of different experiments
will be different. Consider the term Eo∼P
θT ,e,o
bs
[wo(θ)]. If we could compute this term,
the risk would be approximated as:
R ≃ 1
N
∑
θT∈Θ
∑
θ∈Θ
Eo∼P
θT ,e,o
bs
[wo(θ)] r(θ, θT ).
The inner expectation is difficult to compute due to normalization of the weight. We
evaluated it by drawing several outputs o for each θT , and tacking the average of the
corresponding normalized weights.
Estimation of model parameters: we have the possibility to determine some pa-
rameters of the dynamical model. Suppose that the experiment consists in evaluating
parameter i, the “posterior” probability distribution (the distribution which repre-
sents our uncertainty after seeing the result) becomes πθT (θ−i) = πt(θ−i, θi = θT i)
(where the “minus” subscript indicates that we remove the i-th parameter). As in
the previous section, suppose that we have a sample Θ, of size N , drawn from πt.
The expected risk of this experiment becomes:
R = EθT∼πtEθ−i∼πθT r(θ, θT )
where πθT (θ) = πt(θ−i, θi = θT i). Using importance sampling we now can approximate
this risk as:
R ≃ 1
N
∑
θT∈Θ
∑
θ∈Θ
wθT (θ)r(θ, θT )
112 CHAPTER 5. PARAMETER ESTIMATION
where wθT (θ) ∝ πt(θ−i,θi=θT i)πt(θ) (see also chapter 2). Weights should also be normalized
properly in order to compare different experiments.
5.3 Results and discussion
5.3.1 Experimental results
Sub network
We considered testing the proposed method with a small sub-network. We took
the same architecture as in figure 5.1 only considering proteins 6, 7 and 8. There
are 6 variables which behaviour is governed by 13 parameters in this network. Since
the method is based on random-walk type exploration of probability distributions, we
simulated the design process 10 times with different pseudo-random number generator
seeds and same initial credit budget. We compared sampling from a single mode
and sampling from several modes as well as random and active experimental design.
Sampling from several modes means that we combine samples from several Markov
chains initialized using BFGS local search starting from different initialization points.
The results are presented in figure 5.3 and figure 5.4. It appears that given the same
sampling method (exploring several modes), our strategy leads to a better use of
available credits to estimate parameters. Indeed, the risk of the estimated parameter
value is significantly higher in the case of random design (see figure 5.4). Additionally,
exploring only a single mode at each step leads to much more variables estimates,
making it difficult to reproduce potential good results. The boxplot width is much
larger in this case.
Dream challenge
DREAM7 challenge was the occasion to compare this formulation to other methods
proposed by different teams. Table 5.1 presents the result of all participants. The
evaluation was based on both parameter evaluation and prediction of protein time
course in an unseen experimental setting. First, our method did not perform as well
as other methods. As mentioned in the previouse paragraph, the sampling strategy
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Figure 5.3: Comparison of risk evolution between different strategies on a subnetwork.
The figure shows the true risk at each step of the procedure, i.e. the approximate
posterior distribution is compared to the true underlying parameter which is unknown
during the process. The risk is computed at the center of the posterior sample. The
boxplots represent 10 repeats of the design procedure given the same initial credit
budget. Active design is our strategy while random design consists in choosing ex-
periments randomly. Multimodal means that we explore several modes, i.e. combine
several Markov chain samples with different starting points. Unimodal means that
we only consider one chain. The latest strategy leads to highly variable results. Our
active strategy outperforms the random design, we choose experiments that leads to
a better use of available credits, making it possible to perform more experiments at
the end.
greatly affects the performances of the method. One of the reasons for this result is
that we did not carefully tune the sampling and prior parameters when purchasing
data during the challenge. Second, the ability to predict well dynamical behaviour
does not seem to be strongly linked to the ability to infer parameters accurately.
Additional comments on this are given in section 5.3.2. Figure 5.5 compares predicted
and true trajectories in the unseen experimental setting used for the evaluation at
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Figure 5.4: Comparison of final risks after all credit has been spent for different strate-
gies on a subnetwork. The figure shows the true risk at the end of the procedure, i.e.
the approximate posterior distribution is compared to the true underlying parameter
which is unknown during the process. The risk is computed at the center of the pos-
terior sample. The boxplots represent 10 repeats of the design procedure given the
same initial credit budget. Active design is our strategy while random design consists
in choosing experiments randomly. Multimodal means that we explore several modes,
i.e. combine several Markov chain samples with different starting points. Unimodal
means that we only consider one chain. It is clear from this plot that combining
multimodal search and active design is beneficial.
the end of the challenge.
An illustration of method behaviour
The first data we had at hand were low resolution mRNA time courses for the wild
type (no perturbation of the system). The first experiments chosen by the method
were wild-type protein concentration time courses. This makes sense since we have
enormous uncertainty about proteins time courses because we do not know anything
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Team Dparam p-value Dprot p-value Score
orangeballs 0.0229 3.25E-03 0.0024 1.21E-25 27.40
Team 387 0.8404 1.00E+00 0.0160 3.39E-18 17.47
Team 93 0.1592 6.00E-01 0.0354 4.45E-15 14.57
Team 509 0.0899 1.88E-01 0.0475 6.28E-14 13.93
Team 374 0.1683 6.45E-01 0.0979 4.01E-11 10.59
Team 197 0.0453 1.37E-02 0.1988 1.93E-08 9.58
Team 202 0.1702 6.45E-01 0.3625 2.90E-06 5.73
Team 450 0.8128 1.00E+00 0.3564 2.53E-06 5.60
Team 111 0.3766 9.99E-01 0.8180 1.34E-03 2.87
Team 78 0.0699 9.83E-02 19.3233 1.00E+00 1.01
Team 408 0.1883 7.29E-01 3.2228 6.90E-01 0.30
Team 626 5.0278 1.00E+00 14.7744 1.00E+00 0
Table 5.1: Results of DREAM7 Network Topology and Parameter Inference Chal-
lenge. Two criteria were used to compare teams. The first one (column 2) is related
to precision of parameter estimation. The second one (Column 4) is related to pre-
diction of protein time course for an unseen experimental setting. p-values were
computed using a bootstrap procedure. The global score aggregates both criteria.
about them. Once we have purchased these datasets we ran our procedure to deter-
mine what the next experiment should be. Interestingly, the perturbations with the
lowest risk were related to gene 7 which is on the top of the cascade (see figure 5.1) as
shown in table 5.2. Moreover it seemed obvious from table 5.2 that we had to observe
protein 8 concentration. Indeed, figure 5.6 shows that there is a lot of uncertainty
about protein 8 evolution when we remove gene 7. Moreover, our criterion determined
that it was better to observe protein 3 than protein 5, which makes sense since the
only protein which affects protein 5 evolution is protein 8 (see figure 5.1). Therefore
uncertainty about protein 5 time course is tightly linked to protein 8 time course, and
observing protein 3 brings more information than observing protein 5. This might
not be obvious when looking at the graph in figure 5.6 and could not have been fore-
seen by a method that considers uncertainty about each protein independently. At
this point, we purchased protein 3 and 8 time courses for gene 7 deletion experiment
which results are available in figure 5.6.
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Figure 5.5: Comparison between the true time course trajectory and protein time
course prediction. This corresponds to the second criterion for the evaluation of
participants to the challenge (table 5.1).
Parameter and time trajectory variability
Figure 5.7 represents a sample from the posterior distribution after all credits had
been spent and no further experiments could be conducted. Both parameter values
and protein time course for the unseen experiment are presented. All parameters
have been optimized using local optimization. Some parameter clearly concentrate
around a single value while some other have very wide range with multiple accumu-
lation points. Despite this variability in parameter values, the protein time course
trajectories are very similar.
5.3.2 Discussion
Generalizability of the proposed framework
As stated in the introduction, one of the motivation for the approach we consider
was to build a method that is not specific to one instance of the problem and could
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Risk Cost Experiment Observe proteins
771 1200 Delete gene 7 3-8
1196 850 Decrease gene 7 RBS activity 3-8
1290 750 Knock down gene 7 3-8
1957 850 Decrease gene 7 RBS activity 3-7
2254 850 Decrease gene 7 RBS activity 7-8
2554 1200 Delete gene 9 3-8
2867 750 Knock down gene 7 8-9
4647 1200 Delete gene 7 8-9
4798 850 Decrease gene 7 RBS activity 8-9
4928 850 Decrease gene 7 RBS activity 5-8
Table 5.2: Estimation of the expected risk at a certain stage of the experimentation,
ten lowest values. There is consistency in the type of experiment to be conducted
(targeting gene 7 which expression impacts on a big part of the network) and the
quantities to measure (protein 8 almost all the time and protein 3 quite often). Figure
5.6 illustrate this point further.
Figure 5.6: Corresponds to table 5.2 figures. We plot trajectories from our posterior
sample (protein 8 concentration was divided by 2 and we do not plot concentrations
higher than 100). The quantities with the highest variability are protein 8 and 3
concentrations. This is consistent with the estimated risks in 5.2. There is quite
a bit of uncertainty in protein 5 concentration, however this is related to protein 8
uncertainty as protein 8 is an inhibitor of protein 5. Moreover, mRNA concentration
have much lower values and are not as informative as proteins concentrations. Red
dots shows the data we purchased for this experiment after seeing these curve and in
accordance with results in table 5.2.
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Figure 5.7: Comparison of parameter variability and time course trajectory variability.
This is a sample from the posterior distribution after spending all the credits in the
challenge. The top of the figure shows parameter values on log scale, while the bottom
shows prediction of protein time courses for an unseen experiment. The range of some
parameter values is very wide while all these very different values lead to very similar
protein time course predictions.
handle different structures using the same tools. A good experimental design strategy
should perform well on large variety of dynamical systems and not rely on specific
assumptions that are valid only for a few network structures. This is in our opinion
a key point in order to be able to deal with large scale networks of size comparable
that of a cell for example. Moreover, the experimental design strategy should produce
results that are reproducible.
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In order to be able to reproduce experimental results related to the experimental
design problem (for example to compare between different strategies), one needs to
make decision based on a well specified numerical criterion, which could aggregate
several criteria, not requiring human subjectivity. For DREAM7 challenge, our strat-
egy did not compare well to other strategies, as results presented in table 5.1 suggest.
Indeed, the strategy relies on sampling methods which should be tuned to perform
well on specific problems. Comparison of different sampling strategies was done a
posteriori. For the challenge, we used a sampling strategy that did not give results
with accurate reproducibility.
Our method would theoretically handle more complex systems, the limit being the
computational cost of simulating larger networks and exploring higher dimensional
parameter spaces. Different strategies for parameter space exploration and uncer-
tainty evaluation could be investigated for larger networks. We chose to use samples
from the parameter space because of the high multimodality of the likelihood func-
tion. A common approach in active design is to use single parameter value and to
measure dispersion of the likelihood around this point of the space. Our experiments
suggest that this approach does not lead to consistently reproducible results.
Parameter estimation versus network behaviour inference
As observed from the results of different challenge participants in table 5.1, better
parameter estimates do not necessarily lead to better reproduction of the original
system’s behaviour. Moreover, in our setting, as posterior distributions do not con-
centrate strictly around a single mode, many different parameters from different areas
of the parameter space lead to similar fit to the data. This was illustrated in sec-
tion 5.3.1 (see also figure 5.7) and has already been observed on similar numerical
simulations in [97]. These facts question the idea of single parameter estimation and
highlight the importance of reproducing the original dynamical system behaviours
compared to parameter estimation. Such observations are based on computer experi-
ments where the data is ‘clean’, meaning that the noise model and dynamics are well
specified. The effect highlighted here might be even more important in the study of
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real dynamical systems where data is not generated from a model. Indeed, experi-
ments conducted in [34] applying inverse methods to inference of kinetic parameters
based on real data suggest that finding a single parameter value is out of reach and
leads to biologically unrealistic parameter values. They point out the need to address
this problem. The Bayesian framework is an elegant alternative replacing the single
parameter strategy by probability distributions over parameter space. Its main draw-
back lies in higher computational cost. The natural research direction suggested here
is the design of efficient Bayesian inference methods for this specific kind of setting.
5.4 Conclusion
Computational systems biology is a promising line of research based on the heavy use
of computational resources to improve the understanding of the complexity under-
lying cells biology. The most widespread approach is to specify a dynamical model
of the studied biological process based on biochemical knowledge, and consider that
the real system follows the same dynamics for some kinetic parameter value. Recent
reports suggest that this has benefits in practical applications (e.g. [68]). System-
atic implementation of the approach requires to deal with the fact that some kinetic
parameters might be unknown. This raises the issue of estimating these parameters
from experimental data as efficiently as possible. An obvious sanity check is to recover
kinetic parameters from synthetic data where dynamic and noise model are well spec-
ified. This is already quite a challenge. The method we proposed takes advantage
of the Bayesian framework to sequentially choose experiments to be performed, in
order to estimate these parameters subject to cost constraints. The method relies on
a single numerical criterion and does not depend on specific a specific instance of this
problem. Experimental results suggest that the strategy works better than random
experimental choice, even though it is not optimal on specific networks where more
fine tuned strategies improve accuracy of kinetic parameter inference. We evidenced
the mechanisms underlying these observations.
The approach focusing on kinetic parameter estimation is questionable. We give
empirical evidences similar to these of [97] that raises the issue of well posedness of
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this approach showing that very different parameter values could produce very similar
dynamical behaviours, potentially leading to non-identifiabilities. Moreover, focusing
on parameter estimation supposes that the dynamical model represents the true un-
derlying chemical process. In some cases, this might be false. For example, hypotheses
underlying the law of mass action are not satisfied in the gene transcription process.
However, simplified models might still be good proxies to characterise dynamical be-
haviours we are interested in. The problem of interest here is to reproduce dynamics
of a system in terms of observable quantities, and to predict the system behaviour for
unseen manipulations. Parameters can be treated as latent variables which impact
the dynamics of the system but cannot be observed. In this framework, the Bayesian
formalism described here is well suited to tackle the problem of experimental design.
The natural continuity of this work is to adapt the method to treat larger prob-
lems. This raises computational issues and requires to develop numerical methods
that scale well with the size of the problem. The main bottlenecks are the cost of
simulating large dynamical systems, and the need for large sample size in higher
dimension for accurate posterior estimation. Promising research directions are pa-
rameter estimation methods that do not involve dynamical system simulation such
as [18] or differential equation simulation methods that take into account both pa-
rameter uncertainty and numerical uncertainty such as the probabilistic integrator of
[23].
Chapter 6
Conclusion
The common denominator to the studies presented in this thesis is the use of compu-
tational statistics for studying biological phenomena. The main motivation behind
the use of such methods is the complexity of the underlying tasks. The example of
unsupervised correlation based methods and model based clustering methods given
in chapters 3 and 4 show that it is possible to use such methods in order to extract
relevant information. Here, the complexity of the task is related to the quantity of
data that renders non automatized inspection prohibitive. In chapter 5, the complex-
ity of the task stems from highly non linear behaviour of the studied system. In these
cases computer aided methods are essential to tackle the underlying question.
Computer aided biology dates back to the middle of the nineties and has now
specialized into several specific biology related tasks such as data management and
interpretation, technology specific workflows or genomic medicine [92]. Most of the
biomedical research currently heavily relies on the integration of technological plat
forms, database knowledge, biology and computation. This makes biology one of the
largest field of application of computational statistics. The increasing complexity of
tasks related to biological research suggests that both fields will remain intimately
linked in the future.
Extension of the proposed methods are related to the challenges that the field has
to face for the next years. At the molecular scale, more and more information about
chemical and biological assays of various nature are publicly available. Molecular
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representation is the key issue in prediction. Indeed, poor data representation sets
the best performance achievable by any prediction algorithm at a very low level.
Stacking information from many sources can help improve the representation of small
molecules. Among the relevant related questions are:
• How to integrate heterogeneous molecular information in a scalable way?
• Does this integration improve performances over specific prediction task?
• Does richer representation systematically leads to better prediction performances?
The last question is of interest beyond the field of computational chemistry and
chemogenomics. Indeed, motivated by the explosion of the quantity of data available,
a general trend in many related fields, is to integrate as many sources of information
as possible regardless of their relevance to the task at hand. A natural question is
whether this is a good idea or not. Indeed stacking sources of information increases the
likelihood of including the most relevant information in the set of available sources but
also diminishes the ability of anyone to distinguish between relevant and irrelevant
information for a specific task. It might be needed to consider how information
sources are related to the physical reality of the studied process. In the field of
computational chemistry for example, an interesting research direction is to build and
evaluate a similarity measure between molecules that reflect the underlying chemistry.
Using expert systems such as in [69] could for example allow to predict the chemical
complexity of turning one specie into another.
Building generative models based on cell imaging assays is becoming a popular
method to explore and summarize results of fluorescent microscopy cell imaging ex-
periments (for example [138]). Generative models allow to represent the hierarchy
of scales explicitly in their structure. Such models are very popular in unsupervised
modelling of text corpora [14]. Using such hierarchy in the context of fluorescent
cell microscopy could allow to perform phenotypic inference jointly at different levels
of the phenotypic scale and to share information between different scales in a well
defined manner.
As for dynamical systems as considered in chapter 5, the main bottleneck is the
high computational cost of simulating the system accurately. However, given that
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the system parameter values are also uncertain, one may not need to perform very
accurate simulations in order to perform accurate inference. A very fruitful area
of research in machine learning is the investigation of tradeoffs between statistical
and computational accuracy. Understanding these tradeoffs leads to massive saving
in computational requirement of statistical tasks [16]. Similar tradeoffs might exist
when performing inference based on undetermined control problems such as the one
considered in chapter 5. At the heart of these tradeoffs lies the question of propagating
uncertainty in highly non-linear systems. Efficient methods to achieve this task will
probably increase significantly the size of problems of the type of the one considered
in 5 that can be tractably handled.
The results presented in this thesis are based on numerical experiments. We
demonstrated that the output of these experiments were relevant for the related
biological question. These manipulations suggest that the methods described in this
thesis could be used for field applications. However, we did not explicitly provide
examples of biological discoveries made possible thanks to them. This would be the
ultimate goal, a longer term challenge. The only way to actually show that the
proposed approaches are useful is to implement them as part of the tools available
for projects which ultimate objective is to solve a biological problem. The time scales
for this types of projects much wider.
Lastly, a critical point for the usefulness of a method is its computational tractabil-
ity. This is most striking in the work presented in chapter 5 where the amount of
computation required to implement the method on a medium scale problem was
considerable. When designing a protocol to solve a biology related problem, one is
provided with state-of-the-art algorithmic tools that come from different fields such as
computer science, optimization or control. Understanding how efficiently a problem
can be solved on a computer and proposing efficient algorithms for abstract problem,
in addition to be interesting questions by themselves, directly influence the ability
of solving numerical problems. Among others, the field of computer aided biology
benefits directly from these advances. Considering the need to adopt systems point
of views to improve the understanding of complex biological systems behaviours, al-
gorithmic and complexity questions are keys for future biological advances.
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Appendix A
Copulas
Copulas became popular in statistical litterature at the end of the twentieth century.
However, the study of these objects goes back to the middle of the century [88]. We
present here a brief review of the copula framework.
A.1 Definition and example
A copula is a joint multivariate (cumulative) distribution which univariate marginals
are uniform over [0, 1]. More formaly, let U1, . . . , Ud ∈ [0, 1]d d uniform random
variables, Ui ∼ U . A copula C : [0, 1]d → [0, 1] is a joint distribution function
C(u1, . . . , ud) = P (U1 ≤ u1, . . . , Ud ≤ ud)
Let X = {X1, . . . , Xd} a finite set of real valued random variables and let FX (x1, . . . , xd) =
P (X1 ≤ x1, . . . , Xd ≤ xd) a cumulative distribution function over X . The importance
of copulas comes from the fact that any distribution can be formalized in term of
copula [110].
Sklar theorem (1959) Let FX be any multivariate distribution over real-valued
random variables, then there exists a copula function such that
FX (x1, . . . , xd) = C(F1(x1), . . . , Fd(xd))
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Where the Fi are the correponding univariate marginals. If each Fi is continuous then
C is unique.
Conversely, since for any univariate random variable X with cumulative distri-
bution F , the random variable F (X) is uniformly distributed over [0, 1], any copula
taking these transformed univariate marginals {F1(X1), . . . , Fd(Xd)} as its arguments
defines a valid distribution function which univariate marginals are specified. From
a modeling point of view, this allows to separate the choice of univariate marginals
and the choice of the joint dependence structure when constructing a distribution.
Copula based densities Since the joint cumulative distribution function can be
expressed in term of copula, the joint density can also be specified in term of copula
density. If x = (x1, . . . , xd), let F (x) = C(F1(x1), . . . , Fd(xd)) a distribution over X
with d-order partial derivatives. The corresponding density can be expressed as
f(x) =
∂dF (x)
∂x1, . . . , ∂xd
(A.1)
=
∂dC(F1(x1), . . . , Fd(xd))
∂F1(x1), . . . , ∂Fd(xd)
∏
i
fi(xi)
= c(F1(x1), . . . , Fd(xd))
∏
i
fi(xi)
Where c is a copula density function and fi is the univariate density corresponding
to Fi. There are many ways to define and construct copulas, see [88] for a general
review. We focus here on one specific copula family which is defined from multivariate
gaussian distributions.
The gaussian copula This copula family describes the denpendance structure of
multivariate gaussians. It has been introduced in 2000 [132]. Let φ and Φ the standard
(zero mean, unit variance) univariate normal density and cumulative distribution
respectively. Φ−1 is the corresponding quantile function. A general univariate normal
with mean µ and standard deviation σ has a density function f1(x) =
φ(xs)
σ
and
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cumulative distribution function F1(x) = Φ(xs) where xs =
x−µ
σ
corresponds to x
scaled.
Let X = {X1, . . . , Xd} a d-dimensional random variable which follows a multi-
variate normal distribution with correlation matrix R. If x = (x1, . . . , xd) ∈ Rd,
let {µi, σi} the mean and standard deviation of Xi and xsi = xi−µiσi for all i, xs =
(xs1, . . . , xsd) ∈ Rd. The d dimensional multivariate normal density describing X can
be expressed as
fd(x) =
1
(2π)
d
2 |R| 12 ∏di=1 σi exp(−
1
2
xTs Rxs) (A.2)
=
1
|R| 12 exp(−
1
2
xTs (R
−1 − I)xs)
d∏
i=1
φ(xsi)
σi
We have xsi = Φ
−1(Φ(xsi)) = Φ
−1(Fi(xi)) where Fi is the univariate marginal dis-
tribution related to xi. Moreover , we have seen that
φ(xsi)
σi
is the univariate marginal
density related to xi. Identifying the density formulation in (A.2) with the general
formulation in (A.1) allows to define the gaussian copula density. Let R a correlation
matrix and {U1, . . . , Ud}, d random variables uniform over [0, 1].
cg : (u1, . . . , ud)→ 1|R| 12 exp(−
1
2
uTs (R
−1 − I)us)
where usi = Φ
−1(ui), is the copula density function describing the joint dependence
structure shared by the multivariate normal distributions which correlation matrix is
R. This definition is independent of the univariate marginal, therefore pluging any
univariate marginal in this formulation allows to construct density functions which
have a gaussian dependence structure and a different domain for example.
A.2 Copula models parameters estimation
Let {Fθ1 , . . . , Fθd} a set of univariate marginal distributions and {fθ1 , . . . , fθd} the cor-
responding univariate densities parametrized by θF = {θ1, . . . , θd}. Let cθc a copula
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density function parameterized by θc. We are concerened with finding the parameters
Θ = {θF , θc)} which fit the best to a set of n d-dimensional data points: {x1, . . . ,xn}.
We review three common procedures. Let PF,c,Θ : x→ cθc(Fθ1(x1), . . . , Fθd(xd))
∏
i fθi(xi)
the density function associated to the parameter Θ.
A.2.1 Maximum likelihood
The most logical approach is to find Θˆ which is defined as
Θˆ = argmax
Θ
n∏
k=1
PF,c,Θ(xk)
This estimator enjoys consistency and assymptotical normality under regularity
conditions [25]. It is well suited to problems which optimal parameters can be esti-
mated in closed form which is not the case here. Numerical optimization is needed,
wich becomes very heavy when the dimension increases.
A.2.2 Inference functions for margin
This two stage estimation has been introduced by [109] for the bivariate case and by
[63] in the general case. First the univariate marginal parameters are estimated inde-
pendently from the copula. In a second stage, the copula parameters are estimated
given the univariate marginal parameters. For all i,
θˆi = argmax
θi
n∏
k=1
fθi(xki)
Wich defines θˆF = {θˆ1, . . . , θˆd} and fixes the univariate marginals. θc is then
estimated as follows.
θˆc = argmax
θc
n∏
k=1
PF,c,θc,θˆF (xk)
The copula parameter estimate is consistent with assymptotic normality [109].
Moreover, the whole set of estimators Θˆ = {θˆF , θˆc} has the same property [64].
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This procedure is way less expensive computationally than the maximum likelihood
estimator.
A.2.3 Semi-parametric estimation
The inference functions for margin method relies on univariate marginals parameter
estimation as a first stage. This estimations procedure relies on the parametrization
of univariate marginals. [40] proposes a semi-parametric alternative using a non para-
metric estimate of the univariate marginals. The univariate marginals are replaced
by their scaled empirical cumulative distribution function. This amounts to work
with standardized ranks instead of original variables. For all i, let F ∗i stand for
n
n+1
times the i-th univariate marginal empirical distribution function. The scaling factor
ensures that our observations strictly stay in ]0, 1[. The estimator θˆc of the copula
parameter is then
θˆc = argmax
θc
n∏
k=1
cθc(F
∗
1 (xk1), . . . , F
∗
d (xkd))
This estimator is consistent and assymptotically normal [40]. The criterion to
optimize is sometimes called pseudo-likelihood due to its similarities with conventional
likelihood. In this formulation, the copula parameter estimation does not rely on
the univariate marginal parameters, both can be estimated separately. It can be
shown that the asymptotic variance of this estimator is higher than that of maximum
likelihood estimation. However, [72] showed empirically that this last procedure is
more robust to marginals mispecification than the two preceding ones.
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DREAM7 parameter estimation
challenge dynamic equations
[as1] =
(
[p1]
r1Kd
)r1h
1 +
(
[p1]
r1Kd
)r1h
[as2] =
(
[p1]
r2Kd
)r2h
1 +
(
[p1]
r2Kd
)r2h
[as3] =
(
[p4]
r5Kd
)r5h
1 +
(
[p4]
r5Kd
)r5h
[as5] =
(
[p8]
r13Kd
)r13h
1 +
(
[p8]
r13Kd
)r13h
[as6] =
(
[p9]
r9Kd
)r9h
1 +
(
[p9]
r9Kd
)r9h
[as7] =
(
[p6]
r12Kd
)r12h
1 +
(
[p6]
r12Kd
)r12h
[as9] =
(
[p6]
r11Kd
)r11h
1 +
(
[p6]
r11Kd
)r11h
[rs1a] =
1
1 +
(
[p2]
r4Kd
)r4h
[rs1b] =
1
1 +
(
[p6]
r8Kd
)r8h
[rs2] =
1
1 +
(
[p3]
r3Kd
)r3h
[rs3] =
1
1 +
(
[p5]
r7Kd
)r7h
[rs7] =
1
1 +
(
[p7]
r6Kd
)r6h
[rs8] =
1
1 +
(
[p9]
r10Kd
)r10h
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[g1] = [as1] · [rs1a] · [rs1b]
[g2] = [as2] · [rs2]
[g3] = [as3] · [rs3]
[g4] = [as4] · [rs4]
[g5] = [as5]
[g7] = [as7] · [rs7]
[g8] = [rs8]
[g9] = [as9]
d ([p1])
dt
= rbs1strength · [v1mrna]− p1degradationRate · [p1]
d ([p1])
dt
= rbs1strength · [v1mrna]− p1degradationRate · [p1]
d ([p2])
dt
= rbs2strength · [v2mrna]− p2degradationRate · [p2]
d ([p3])
dt
= rbs3strength · [v3mrna]− p3degradationRate · [p3]
d ([p4])
dt
= rbs4strength · [v4mrna]− p4degradationRate · [p4]
d ([p5])
dt
= rbs5strength · [v5mrna]− p5degradationRate · [p5]
d ([p6])
dt
= rbs6strength · [v6mrna]− p6degradationRate · [p6]
d ([p7])
dt
= rbs8strength · [v7mrna]− p7degradationRate · [p7]
d ([p8])
dt
= rbs7strength · [v8mrna]− p8degradationRate · [p8]
d ([p9])
dt
= rbs9strength · [v9mrna]− p9degradationRate · [p9]
d ([v1mrna])
dt
= pro1strength · [g1]− v1mrnaDegradationRate · [v1mrna]
d ([v2mrna])
dt
= pro2strength · [g2]− v2mrnaDegradationRate · [v2mrna]
d ([v3mrna])
dt
= pro3strength · [g3]− v3mrnaDegradationRate · [v3mrna]
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d ([v4mrna])
dt
= pro4strength · [g4]− v4mrnaDegradationRate · [v4mrna]
d ([v5mrna])
dt
= pro5strength · [g5]− v5mrnaDegradationRate · [v5mrna]
d ([v6mrna])
dt
= pro6strength · [g6]− v6mrnaDegradationRate · [v6mrna]
d ([v7mrna])
dt
= pro7strength · [g9]− v7mrnaDegradationRate · [v7mrna]
d ([v8mrna])
dt
= pro9strength · [g7]− v8mrnaDegradationRate · [v8mrna]
d ([v9mrna])
dt
= pro8strength · [g8]− v9mrnaDegradationRate · [v9mrna]
Applications de l'apprentissage statistique à la biologie computationnelle
RÉSUMÉ :  Les biotechnologies sont arrivées au point ou la quantité d'information disponible permet de 
penser  les objets  biologiques  comme des systèmes complexes.  Dans ce contexte,  les phénomènes qui 
émergent  de  ces  systèmes  sont  intimement  liés  aux  spécificités  de  leur  organisation.  Cela  pose  des 
problèmes computationnels  et  statistiques qui  sont précisément  l'objet  d'étude de la communauté liée à 
l'apprentissage statistique. Cette thèse traite  d'applications de méthodes d'apprentissage pour  l'étude de 
phénomène biologique dans une perspective de système complexe. Ces méthodes sont appliquées dans le 
cadre de l'analyse d'interactions protéine-ligand et d'effets secondaires, du phenotypage de populations de 
cellules et du plan d'expérience pour des systèmes dynamiques non linéaires partiellement observés.
D'importantes quantités de données sont désormais disponibles concernant les molécules mises sur 
le  marché,  tels  que  les  profils  d'interactions  protéiques  et  d'effets  secondaires.  Cela  pose  le  problème 
d'intégrer  ces données  et  de  trouver  une forme de  structure  sous tendant  ces  observations  à grandes 
échelles. Nous appliquons des méthodes récentes d'apprentissage non supervisé à l'analyse d'importants 
jeux de données sur des médicaments. Des exemples illustrent la pertinence de l'information extraite qui est  
ensuite validée dans un contexte de prédiction.
Les variations de réponses à un traitement entre différents individus posent le problème de définir 
l'effet d'un stimulus à l'échelle d'une population d'individus. Par exemple, dans le contexte de la microscopie 
à haut débit, une population de cellules est exposée à différents stimuli. Les variations d'une cellule à l'autre 
rendent la comparaison de différents traitement non triviale. Un modèle génératif est proposé pour attaquer 
ce problème et ses propriétés sont étudiées sur la base de données expérimentales.
A l'échelle moléculaire, des comportements complexes émergent de cascades d'interactions non 
linéaires entre différentes espèces moléculaires. Ces non linéarités engendrent des problèmes d'identifiabilité 
du système. Elles peuvent cependant être contournées par des plans expérimentaux spécifiques, un des 
champs de recherche de la biologie des systèmes. Une stratégie Bayésienne itérative de plan expérimental 
est proposée est des résultats numériques basés sur des simulations in silico d'un réseau biologique sont 
présentées.
Mots  clés :  Apprentissage  statistique,  biologie  computationnelle,  conception  de  médicaments, 
microscopie haut débit, biologie des systèmes.
Applications of machine learning in computational biology
ABSTRACT : Biotechnologies came to an era where the amount of information one has access to allows to 
think about biological objects as complex systems.  In this context, the phenomena emerging from those 
systems  are  tightly  linked  to  their  organizational  properties.  This  raises  computational  and  statistical 
challenges which are precisely the focus of study of the machine learning community. This thesis is about 
applications of machine learning methods to study biological phenomena from a complex systems viewpoint. 
We apply machine learning methods in the context of protein-ligand interaction and side effect analysis, cell 
population phenotyping and experimental design for partially observed non linear dynamical systems.
Large amount  of  data is available about  marketed molecules,  such as protein  target  interaction 
profiles and side effect profiles. This raises the issue of making sense of this data and finding structure and  
patterns that underlie these observations at a large scale. We apply recent unsupervised learning methods to 
the analysis  of large datasets of marketed drugs. Examples show the relevance of  extracted information 
which is further validated in a prediction context.
The variability of the response to a treatment between different individuals poses the challenge of 
defining the effect of this stimulus at the level of a population of individuals. For example in the context High 
Content  Screening,  a population of  cells is  exposed to different  stimuli.  Between cell  variability within  a 
population  renders  the  comparison  of  different  treatments  difficult.  A  generative  model  is  proposed  to 
overcome this issue and properties of the model are investigated based on experimental data.
At the molecular scale, complex behaviour emerge from cascades of non linear interaction between 
molecular species. These non linearities leads to system identifiability issues. These can be overcome by 
specific experimental plan, one of the field of research in systems biology. A Bayesian iterative experimental  
design  strategy is  proposed and numerical  results  based on  in  silico  biological  network  simulations  are 
presented.
Keywords : Machine learning, Computational Biology, Drug Design, High Content Screening, Systems 
biology
